Page last updated: 2024-08-18

pyrroles and Arthritis, Rheumatoid

pyrroles has been researched along with Arthritis, Rheumatoid in 428 studies

Research

Studies (428)

Timeframe	Studies, this research(%)	All Research%
pre-1990	60 (14.02)	18.7374
1990's	1 (0.23)	18.2507
2000's	25 (5.84)	29.6817
2010's	270 (63.08)	24.3611
2020's	72 (16.82)	2.80

Authors

Authors	Studies
Iwasawa, M; Juji, T; Maenohara, Y; Matsumoto, T; Nakamura, I; Omata, Y; Takahashi, H; Tanaka, S; Uchio, A	1
Feng, Y; Shi, Y; Xie, Y; Zhang, G	1
Bensimon, A; Bergman, M; Clewell, J; Orvis, E; Tundia, N; Yang, M	1
Bode-Böger, SM; Feist, E; Martens-Lobenhoffer, J; Tomaras, S	1
Choy, EH; Dews, SA; Galloway, J; Raine, T; Rivett, L; Roberts, J	1
Desai, RJ; Khosrow-Khavar, F; Kim, SC; Lee, H; Lee, SB	1
Askling, J; Barbulescu, A; Chatzidionysiou, K; Forsblad-d'Elia, H; Frisell, T; Kastbom, A; Lindström, U; Turesson, C	1
Bessette, L; Kinch, CD; Kwok, K; Lukic, T; Mysler, E; On, PV; van Vollenhoven, RF	1
Abello, M; Amador, L; Castillo, D; Gutierrez-Ardila, MV; Guzman, R; Izquierdo, J; Lukic, T; Madariaga, H; Otero, W; Ponce de Leon, D; Reyes, J; Velez, P	1
Cohen, SB; Winthrop, KL	1
Bartlett, SJ; Bingham, CO; Cella, D; Gold, DA; Gruben, D; Murray, C; van Vollenhoven, R	1
Llevat, N; Montoro, M; Román Ivorra, JA	1
Arbrile, M; Baldovino, S; Barinotti, A; Buccarano, N; Cecchi, I; Crosasso, P; Di Gregorio, F; Di Nunzio, P; Favuzzi, MD; Menegatti, E; Milone, V; Osella, S; Radin, M; Roccatello, D; Rossi, D; Sciascia, S	1
Álvaro-Gracia, JM; Curtis, JR; Dikranian, AH; Gonzalez-Gay, MA; Paulissen, J; Shi, H; Stockert, L; Takiya, L; Tatulych, S; Wellborne, F	1
Amin, S; Khenat, A; Malandkar, M; Phatak, S	1
Choquette, D; Galos, C; Gruben, D; Haraoui, B; Keystone, EC; Khraishi, M; Kinch, C; Lisnevskaia, L; Roy, P; Sampalis, JS; Teo, M; Vaillancourt, J; Woolcott, JC	1
Landewé, R; Ramiro, S; van der Heijde, D	1
Leng, X; Sun, B; Yang, H; Zeng, X; Zhang, W; Zhou, J; Zhou, S	1
Balanescu, AR; Bhatt, DL; Chen, AS; Citera, G; Connell, CA; Gold, D; Pascual-Ramos, V; Pope, JE; Sawyerr, G; Schulze-Koops, H; Shapiro, AB	1
Jung, JY; Kim, HA; Kim, JW; Lee, E; Suh, CH	1
Isomäki, P; Kuuliala, A; Kuuliala, K; Leirisalo-Repo, M; Palmroth, M; Peltomaa, R; Silvennoinen, O; Valli, A; Vidqvist, KL; Virtanen, A	1
Cañada Martínez, AJ; Fragío Gil, JJ; González Mazarío, R; González Puig, L; Grau García, E; Ivorra Cortés, J; Negueroles Albuixech, RM; Román Ivorra, JA	1
Charles-Schoeman, C; Hyde, C; Martin, DA; Paciga, SA; Sahin, B; Szekanecz, Z; Vranic, I; Wang, Z; Weitz, JI	1
Jeon, JY; Jo, JY; Ju, JH; Lee, EB; Sung, YK; Yoo, HJ	1
Bertolini, N; Caso, F; Costa, L; Del Puente, A; Luppino, JME; Mostacciuolo, E; Passavanti, S; Peluso, R; Santelli, F; Scarpa, R; Tasso, M	1
Bhatt, DL; Chen, YH; Connell, CA; Curtis, JR; Gómez-Reino, JJ; Gunay, LM; Menon, S; Sugiyama, N; Vranic, I; Wang, C; Wu, J; Yamaoka, K	1
Bhatt, DL; Buch, MH; Charles-Schoeman, C; Connell, CA; Dougados, M; Giles, JT; Koch, GG; Kwok, K; Menon, S; Rivas, JL; Szekanecz, Z; Vranic, I; Wang, C; Wu, J; Yndestad, A; Ytterberg, SR	1
Bingham, CO; Brault, Y; Dougados, M; Fallon, L; Kessouri, M; Roychoudhury, S; Taylor, PC; Wang, L	1
Ding, NS; Gilmore, R; Tassone, D	1
Cheng, X; Dai, SM; Du, F; Hu, Q; Jiang, L; Liu, H; Lu, LJ; Ma, L; Shi, H; Su, Y; Tao, YL; Teng, J; Wang, M; Xue, Y; Yang, C; Ye, J; Zhao, D	1
Keystone, EC; Mokbel, A; Movahedi, M; Ojani, P; Philippopoulos, E	1
Barton, A; Bluett, J; Church, S; Hyrich, KL; Ogungbenro, K; Unwin, RD	1
Danese, S; Lasa, JS; Olivera, PA; Peretto, G; Peyrin-Biroulet, L; Zuily, S	1
Choe, JY; Jeon, JY; Kim, SK; Lee, SH; Sun, J; Yoo, HJ	1
Atsumi, T; Bracher, M; Brooks, D; Davies, J; Fleischmann, RM; Goode, C; Gupta, A; McInnes, IB; Mukherjee, S; O'Shea, C; Saurigny, D; Schifano, LA; Shelton, C; Smith, JE; Strand, V; Takeuchi, T; Taylor, PC; van der Heijde, D; Wang, M; Wang, R; Watts, S; Weinblatt, ME	1
Ciurea, A; Distler, O; Frank Bertoncelj, M; Jo, H; Killeen, T; Kwok, K; Ospelt, C; Wang, L	1
Mori, S; Ueki, Y	1
Bessette, L; Crooks, M; Fallon, L; Gold, D; Gruben, D; Haraoui, B; Jones, N; Pope, J; Woolcott, J	1
Krüger, K	1
Andrews, J; Bowes, MA; Chapman, D; Conaghan, PG; Guillard, G; Koenig, A; Stein, A; Troum, O; Wilkinson, B; Xie, Z; Østergaard, M	1
Abria, C; Chaudhari, AJ; Harmany, ZT; Kundu-Raychaudhuri, S; Raychaudhuri, S; Raychaudhuri, SP; Smith, CM	1
DeMasi, R; Fleischmann, R; Gruben, D; Iikuni, N; Moots, RJ; Mysler, E; Smolen, JS; Soma, K; Strand, V; Wallenstein, GV	1
Choy, EH	2
Lei, Y; Li, Y; Lu, J; Shen, H; Xia, L; Yang, J; Yuan, L; Zhang, H	1
Lee, YH; Song, GG	3
Hayashi, S; Itoh, I; Iwano, M; Kasuno, K; Kimura, H; Ojima, T; Shimizu, H; Takahashi, N; Yamamoto, C	1
Kato, F; Kurosaka, D; Oto, Y; Takahashi, Y	1
Dowty, ME; Hegen, M; Jesson, MI; Katkade, V; Lin, TH; Martin, DA; Menon, S; Telliez, JB	1
Chandran, U; Reps, J; Ryan, PB; Stang, PE	1
Bonovas, S; Danese, S; Lasa, JS; Olivera, PA; Peyrin-Biroulet, L	1
Bertoldi, I; Orsolini, G; Rossini, M	1
Estevez, AJ; Papagno, MJ; Vinicki, JP	1
Biswas, P; Chen, C; Choy, EH; Needle, E; Rigby, WF; Soma, K; Valdez, H; Wang, L; Winthrop, KL; Wouters, A	1
Damsky, W; King, B; Peterson, D	1
Betts, KA; Du, EX; Pope, J; Qi, CZ; Sawant, R; Song, Y; Tang, P; Tundia, N	1
Balsa, A; Casado, MA; de Andrés-Nogales, F; Gómez, S; Martinez-Sesmero, JM; Montoro, M; Navarro, F; Oyagüez, I; Peral, C; Valderrama, M	1
Banfield, C; Beebe, JS; Chandra, D; Cox, L; Damjanov, N; Kivitz, A; Mancuso, J; Manukyan, Z; Peeva, E; Radunovic, G; Robinson, MF; Saunders, M; Stamenkovic, B; Vincent, MS	1
Baldovino, S; Buccarano, N; Cecchi, I; Crosasso, P; Di Gregorio, F; Di Nunzio, P; Favuzzi, MD; Foddai, SG; Osella, S; Radin, M; Roccatello, D; Rossi, D; Rubini, E; Sciascia, S; Valeria, M	1
Morinobu, A	1
Alikhan, M; Jogi, R; Nguyen, JK; Patel, AB; Schlichte, MJ	1
Kobak, S	1
Cardiel, MH; Castañeda, O; Chartrand, S; Citera, G; Fischer, A; Girard, T; Kwok, K; Madariaga, H; Mysler, E; Park, JK; Ponce de Leon, D; Richette, P; Rivas, JL; Strengholt, S; Thorat, AV; Wang, L	1
Armuzzi, A; Colombel, JF; Farnier, M; Friedman, GS; Ha, C; Kwok, K; Quirk, D; Salese, L; Sands, BE; Su, C; Taub, PR	1
Chen, Y; Dong, P; Guo, Q; Ma, A; Tian, L; Wang, L; Xiong, X	1
Dörner, T	1
Chen, DY; Chen, HH; Chen, JP; Chen, YH; Chen, YJ; Chen, YM; Hsieh, TY; Huang, WN; Liao, TL	1
Blachley, T; Chen, C; Cohen, SB; Dandreo, KJ; Dougados, M; Greenberg, JD; Gruben, D; Harnett, J; Lenihan, A; Litman, HJ; Lukic, T; Madsen, A; Rivas, JL; Smith, TW; Woolcott, J; Zhang, R	1
Alten, R; Diehl, A; Germino, R; Kaine, J; Murray, CW; Shi, H; Strand, V; Wallenstein, G	1
Kadoba, K; Mukoyama, H; Murabe, H; Nishimura, K; Saito, R; Waki, D; Yokota, T	1
Biswas, P; Charles-Schoeman, C; Chen, C; Cohen, SB; Curtis, JR; Kwok, K; Lee, EB; Madsen, A; Mariette, X; Nash, P; Shapiro, A; Tanaka, Y; Wang, L; Winthrop, KL; Wollenhaupt, J	1
Amuro, H; Ebina, K; Hara, R; Hashimoto, M; Hirano, T; Hirao, M; Jinno, S; Katayama, M; Kumanogoh, A; Maeda, Y; Murata, K; Nakata, K; Okita, Y; Onishi, A; Son, Y; Takeuchi, T; Yamamoto, K; Yamamoto, W; Yoshikawa, A	1
Bhattoa, HP; Bodnár, N; Bodoki, L; Czókolyová, M; Domján, A; Gulyás, K; Hamar, A; Hodosi, K; Horváth, Á; Nagy, G; Panyi, G; Pethő, Z; Pusztai, A; Soós, B; Szamosi, S; Szántó, S; Szekanecz, É; Szekanecz, Z; Szűcs, G; Tajti, G; Végh, E	1
Lee, YH; Sung, YK	1
Li, Y; Sun, Y; Wei, S; Zhang, L; Zong, S	1
Avci, AB; Burmester, GR; Feist, E	1
Aramaki, T; Eguchi, K; Endo, Y; Fujikawa, K; Ichinose, K; Igawa, T; Iwamoto, N; Kawakami, A; Kawashiri, SY; Koga, T; Kurushima, S; Michitsuji, T; Mizokami, A; Nakamura, H; Nishihata, S; Okada, A; Okamoto, M; Origuchi, T; Sato, S; Shimizu, T; Sumiyoshi, R; Suzuki, T; Tamai, M; Tsuji, Y; Ueki, Y	1
Barbich, T; Cerda, OL; Citera, G; Schneeberger, EE	1
Cernea, M; Gupta, AK; Lynde, CW	1
Bijlsma, J; Burmester, G; Chatzidionysiou, K; Dougados, M; Emamikia, S; Landewé, R; Nam, J; Ramiro, S; Scholte, M; Smolen, J; van der Heijde, D; van Vollenhoven, R	1
Mitchell, TS; Moots, RJ; Wright, HL	1
Handa, H; Hosogai, M; Kishi, S; Mitsui, T; Ogawa, Y; Todokoro, D; Yanagisawa, K; Yokohama, A	1
Amano, K; Iwata, K; Kubo, S; Nagano, S; Nagasawa, H; Suematsu, E; Tanaka, Y; Tohma, S; Yamaoka, K	1
Kosinski, M; Mebus, CA; Rendas-Baum, R; Singh, A; Wallenstein, GV; Wilkinson, BE	1
Amital, H; Gertel, S; Karmon, G; Mahagna, H; Watad, A	1
Aramaki, T; Eguchi, K; Fukui, S; Hirai, Y; Horai, Y; Ichinose, K; Iwamoto, N; Kawakami, A; Kawashiri, SY; Koga, T; Nakamura, H; Nishino, A; Origuchi, T; Shimizu, T; Takatani, A; Tamai, M; Terada, K; Tsuji, S; Ueki, Y; Umeda, M	1
Buchbinder, R; Hossain, A; Maxwell, LJ; Mudano, AS; Singh, JA; Suarez-Almazor, ME; Tanjong Ghogomu, E; Tugwell, P; Wells, GA	1
Barrow, AD; Capuder, K; Cella, M; Colonna, M; Gilfillan, S; Lin, LL; Notarangelo, LD; Robinette, ML; Telliez, JB; Ulland, TK	1
Haeffner, F; Hoveyda, AH; Mikus, MS; Mszar, NW; Torker, S	1
Abdel, MP; Brause, B; Chen, AF; Dasa, V; George, M; Gewurz-Singer, O; Giles, JT; Gililland, J; Goodman, M; Goodman, SM; Guyatt, G; Hurley-Rosenblatt, A; Johnson, B; Kirou, K; Lee, S; Losina, E; MacKenzie, R; Mandl, LA; Michaud, K; Mikuls, T; Miller, AS; Mont, MA; Russell, L; Sah, A; Sculco, P; Singh, JA; Sporer, S; Springer, B; Stryker, L; Turgunbaev, M; Yates, A	2
Scott, DL; Stevenson, MD	1
DeMasi, R; Fleischmann, R; Hall, S; Kivitz, AJ; Krishnaswami, S; Luo, Z; Menon, S; Mojcik, C; Moots, RJ; Mysler, E; Smolen, JS; Soma, K; Takiya, L; Tatulych, S; Zhang, R	1
Barrasa, JI; Gratal, P; Herrero-Beaumont, G; Largo, R; Larrañaga-Vera, A; Pérez-Baos, S; Prieto-Potin, I	1
Chen, DY; Chen, YH; Chen, YM; Hsieh, TY; Huang, WN; Lin, CT; Wu, YD	1
Onuora, S	2
Fujishiro, M; Hayakawa, K; Hirai, T; Ikeda, K; Miyashita, T; Morimoto, S; Sekigawa, I; Takamori, K; Takasaki, Y; Tamura, N; Tsushima, H; Yamaji, K; Yoshida, Y	1
Betts, KA; Curtis, JR; Douglas, K; Du, EX; Ganguli, A; Wells, AF	1
Chen, Y; Gao, XM; Gong, FY; Gong, Z; Li, ZJ; Ma, SY; Zhou, Z	1
Poorvashree, J; Suneela, D	1
Fleischmann, R	3
Cush, JJ	1
Biswas, P; Choy, EH; Hodge, JA; Mojcik, CF; Nduaka, CI; Needle, E; Passador, S; Rigby, WF; Soma, K; Winthrop, KL; Wouters, AG	1
Bananis, E; Chen, C; Curtis, JR; Fan, H; Hirose, T; Lindsey, S; Mendelsohn, AM; Nduaka, CI; Tanaka, Y; Valdez, H; Wang, L; Winthrop, KL; Yamaoka, K	1
McHugh, J	1
Biswas, P; Boy, MG; Chen, C; Kwok, K; Mariette, X	1
Chen, L; He, L; Lan, T; Pei, H; Tang, M; Zhang, C	1
Amano, K; Hatta, K; Kanazawa, T; Kume, K; Kuwaba, N; Ohta, H; Yamada, S	1
Chastek, B; Chen, CI; Kuznik, A; Proudfoot, C; Shinde, S; Wei, W	1
Deleuran, B; Eggertsen, PP; Frøling, M; Mikkelsen, C; Stern, M; van de Looij, A	1
Dhillon, S	1
Bananis, E; Burmester, GR; Charles-Schoeman, C; Connell, CA; Fan, H; Fleischmann, R; Kwok, K; Nash, P; van der Heijde, D; Zerbini, CAF	1
Mori, S; Ueki, Y; Yoshitama, T	1
Contreras-Yáñez, I; Ortiz-Haro, AB; Pascual-Ramos, V; Pérez-Román, DI; Ruiz-Medrano, E	1
Barroso, NS; Furst, DE; Miller, EZ	1
An, Y; Kwok, K; Li, G; Li, X; Li, Z; Su, H; Wang, L; Wu, Q; Xu, J; Zheng, Y	1
Bokarewa, MI; Erlandsson, MC	1
Dasic, G; Frajzyngier, V; Jones, T; Madsen, A; Rojo, R; Valdez, H	1
Gladman, D; Mease, P	1
Arbeit, R; Kanhoush, R; Noell, C	1
Hider, SL; Scott, DL; Scott, IC	1
Biswas, P; Brennan, TV; Bukowski, JF; Cheng, J; Clark, JD; Collinge, M; Hammond, C; Hazra, A; Hodge, JA; Jesson, MI; Lan, S; Lin, L; Mojcik, CF; Noveck, RJ; Staats, JS; Stempora, L; Weinhold, KJ; Wouters, A	1
Bermejo, I; Martyn-St James, M; Ren, S; Scott, DL; Stevenson, M; Uttley, L; Wong, R; Young, A	1
Abrahamowicz, M; Bernatsky, S; Curtis, JR; Guerra, SF; Machado, MAÁ; Moura, CS	1
Du, GH; Jian, LL; Li, CH; Liu, XY; Sun, L; Xu, LL; Yu, RH; Zhao, JX	1
Abe, N; Jodo, S; Kudo, T	1
Bananis, E; Bergman, MJ; Dikranian, A; Lee, EB; Strand, V; Takiya, L; Wilkinson, B; Yazici, Y; Zang, C	1
Chapman, D; DeMasi, R; Fallon, L; Keystone, E; Lee, EB; van Vollenhoven, RF; Wilkinson, B; Zwillich, SH	1
Bodycombe, D; Curtis, JR; Dyagilev, K; Kan, HJ; Kharrazi, H; Molta, CT; Saria, S; Schulam, P	1
Biniecka, M; Fearon, U; Gallagher, L; Low, C; McGarry, T; Orr, C; Veale, DJ; Wade, S	1
Bensen, W; Bird, P; El-Zorkany, B; Kaine, J; Manapat-Reyes, BH; Pascual-Ramos, V; Soma, K; Thirunavukkarasu, K; Witcombe, D; Zhang, R	1
Cho, H; Choy, EH; Hashizume, M; John, MR; O'Mahony, A	1
Bourret, JA; Claxton, L; Gerber, RA; Soonasra, A; Taylor, M	1
Yin, Y; Zhang, DY; Zhang, TT	1
Galdamez, J; Goldring, SR; Lele, SM; Liu, Y; Mikuls, TR; Purdue, PE; Soni, DM; Wang, D; Wang, X; Wei, X; Wu, J; Zhao, G	1
Claxton, L; Gerber, RA; Gruben, D; Moynagh, D; Singh, A; Taylor, M; Wallenstein, GV	1
Aguirre-Valencia, D; Naranjo-Escobar, J; Navarro, EP; Posso-Osorio, I; Tobón, GJ	1
Atzeni, F; Gerratana, E; Marino, F; Masala, IF; Nucera, V; Sangari, D; Sarzi-Puttini, P; Talotta, R	1
Bastian, Y; Castañeda-Delgado, JE; Castañeda-Sánchez, JJ; Castillo-Ortiz, JD; Enciso-Moreno, JA; Fernández-Ruiz, JC; González-Amaro, R; Monsivais-Urenda, AE; Ochoa-González, F; Ramos-Remus, C; Romo-García, MF; Sánchez-Corona, J	1
Akylbekova, EL; Brenol, CV; de Leon, DP; García, EG; Lomonte, ABV; Marcolino, FMD; Radominski, SC; Rojo, R; Zerbini, CAF	1
Chen, C; Deng, C; Fan, H; Lamba, M; Lukic, T; Mojcik, C; Stock, T; Sugiyama, N; Tanaka, Y; Toyoizumi, S; Valdez, H; Yuasa, H; Zhang, R	1
Dawwas, GK; Thai, TN	1
Bananis, E; Cohen, S; Connell, CA; Fan, H; Fleischmann, R; Haraoui, B; Kaine, J; Keystone, E; Kivitz, AJ; Takiya, L; van Vollenhoven, RF	1
Bae, SC; Lee, YH	2
Chikugo, M; Harada, N; Iuchi, M; KIshi, J; Kuroda, M; Nishioka, Y; Sakaue, H; Sebe, M; Tsutsumi, R	1
Bernatsky, S; Chen, L; Curtis, JR; Winthrop, K; Xie, F; Yang, S; Yun, H	1
Gru, AA; Junkins-Hopkins, JM; Williams, E	1
Bananis, E; Charles-Schoeman, C	1
Boers, M	1
Adawi, M; Amital, H; Biln, NK; Blank, M; Bragazzi, NL; Gilburd, B; Katz, I; Langevitz, P; Lidar, M; Marotta, A; Perez, D; Shoenfeld, Y; Shovman, O; Watad, A	1
An, Y; Bao, CD; Chen, ZW; Gu, JR; Hwang, LJ; Kremer, J; Li, ZG; Liu, Y; Wang, L; Wu, QZ; Xu, HJ; Zhao, DB	1
Biswas, P; Choy, E; Clark, JD; Hazra, A; Hodge, J; Krishnaswami, S; Lazariciu, I; Lee, EB; Mojcik, C; Strengholt, S; Valdez, H; van Vollenhoven, R; Wang, L	1
Jia, J; Li, W; Liao, W; Liu, W; Ou, F; Su, K; Sun, J; Sun, Y; Zhang, Z; Zheng, Y	1
Desai, RJ; Kim, SC; Pawar, A; Weinblatt, ME	1
Chen, DY; Chen, HH; Chen, JP; Chen, YH; Chen, YM; Hsieh, TY; Huang, WN; Hung, WT; Liao, TL; Yang, SS	1
Cacciapaglia, F; Fornaro, M; Iannone, F; Lopalco, G; Venerito, V	1
Deng, W; Sun, L; Wu, Q; Zhang, Z	1
Bertolo, MB; Brenol, CV; Castelar Pinheiro, GDR; Cruz, BA; de Albuquerque, CP; de Freitas, MVC; Duarte, ALBP; Giorgi, RDN; Gomides, APM; Kakehasi, AM; Laurindo, IMM; Louzada-Júnior, P; Mota, LMHD; Pereira, IA; Ubirajara Silva de Souza, MPG; Xavier, RM	1
Cardiel, MH; Cohen, S; Connell, CA; Fleischmann, R; Gruben, D; Keystone, E; Kremer, J; Nash, P; Song, YW; Strand, V; Tanaka, Y; Tegzová, D; van der Heijde, D; Wallenstein, G; Zerbini, CAF	1
Alegre-Del Rey, E; Camean-Castillo, M; Fenix-Caballero, S; Gimeno-Ballester, V; Rios-Sanchez, E; Vázquez-Real, M	1
De Silva, T; Le Marshall, K; Rischin, A	1
Westhovens, R	1
Taylor, PC	1
Chen, L; He, J; Li, W; Niu, T; Pei, H; Xiang, M; Zhang, C; Zhu, J	1
Bird, P; Connell, CA; Hall, S; Kwok, K; Nash, P; Thirunavukkarasu, K; Witcombe, D	1
Chen, C; Kwok, K; Lee, EB; Liu, Y; Llamado, LJ; Luo, Y; Sugiyama, N; Tanaka, Y; Tsai, WC; Wang, L; Yamanaka, H; Yoo, HJ	1
Cohen, S; Curtis, JR; DeMasi, R; Kwok, K; Lazariciu, I; Lee, EB; Mojcik, C; Silverfield, J; Soma, K; Strengholt, S; Terry, K; Wang, L; Wollenhaupt, J	1
Atzeni, F; Bechman, K; Cope, AP; Galli, M; Galloway, JB; Norton, S; Subesinghe, S; Winthrop, KL	1
Aykara, I; Diller, M; Frommer, K; Hasseli, R; Hülser, ML; Müller-Ladner, U; Neumann, E; Rehart, S	1
Yamaoka, K	3
Chen, CI; Fournier, M; Gal, P; Kiss, Z; Kuznik, A; Michaud, K; Muszbek, N; Proudfoot, C	1
Demidova, NV; Kirillova, IG; Markelova, EI; Misiyuk, AS; Novikova, DS; Popkova, TV; Udachkina, HV	1
Feng, Q; Guo, M; Qiu, Q; Tan, X	1
Almanzar, G; Kienle, F; Maas, A; Prelog, M; Schmalzing, M; Tony, HP	1
Gomides, AP; Mota, L; Neto, LL; Rocha Silva, C; Scheinberg, MA; Winthrop, K	1
Witte, T	1
Chan, EWY; Li, X; Man, KK; Pathadka, S; Wong, ICK	1
Choong, K; Dyer, J; Morwood, K	1
Abud-Mendoza, C; Calabrese, LH; Fleischmann, R; Iikuni, N; Lee, SH; Lindsey, SM; Luo, Z; Soma, K; Takiya, L; Tatulych, S	1
Choi, SJ; Lee, YH; Song, GG	1
Bonelli, M; Dalwigk, K; Hayer, S; Holinka, J; Karonitsch, T; Kiener, HP; Niederreiter, B; Olmos Calvo, I; Pap, T; Platzer, A; Sevelda, F; Smolen, JS; Steiner, G; Superti-Furga, G	1
Almon, RR; DuBois, DC; Jusko, WJ; Song, D; Yu, R	1
Byers, NL; Higgs, RE; Lee, J; Macias, WL; McInnes, IB; Na, S; Ortmann, RA; Rocha, G; Rooney, TP; Taylor, PC; Wehrman, T; Zhang, X; Zuckerman, SH	1
Huang, Z; Kane, S; Lissoos, T; Moran, K; Null, K	1
Biswas, P; Boy, MG; Charles-Schoeman, C; DeMasi, R; Hwang, LJ; McInnes, IB; Soma, K; Valdez, H	1
Bradley, JD; Brosnan, MJ; Connell, CA; Kim, HY; Lee, SH; Luo, Z; Mandel, D; McInnes, IB; Song, YW; Zuckerman, A; Zwillich, SH	1
Bannwarth, B; Kostine, M; Poursac, N	1
Deodhar, A	1
Koch, S; Peyrin-Biroulet, L; Vuitton, L	1
Ferraccioli, G; Gremese, E	1
Benda, B; Bradley, J; Burmester, GR; Gruben, D; Mebus, C	1
Scott, LJ	1
Kawalec, P; Mikrut, A; Pilc, A; Wiśniewska, N	1
Conaghan, PG; Rakieh, C	1
Choi, IA; Kim, JW; Lee, EB; Lee, EY; Song, YW	1
Tanaka, Y; Yamaoka, K	3
Eguchi, K; Izumi, M; Izumi, Y; Jiuchi, Y; Kawakami, A; Kozuru, H; Migita, K; Motokawa, S; Nakamura, M; Nishino, Y; Nonaka, F; Satomura, K; Torigoshi, T	1
Bradley, J; Fleischmann, R; Genovese, M; Gruben, D; Hall, S; Isaacs, JD; Koncz, T; Kremer, J; Krishnaswami, S; Li, ZG; Martin-Mola, E; Riese, R; Wallenstein, G; Zwillich, SH	1
Chan, EW; Chui, CS; He, Y; Lau, WC; Man, KK; Wong, AY; Wong, IC; Worsley, AJ	1
Berhan, A	1
Bandy, JL; Boyce, EG; O'Dell, KM; Vyas, D	1
Chen, Y; Liang, F; Shi, P; Wang, Q; Wei, D; Xiao, X; Yao, L; Yin, X; Zhang, X	1
Buch, MH; Gaujoux-Viala, C; Gossec, L; Landewé, R; Nam, J; Ramiro, S; Smolen, JS	1
Fukuyo, S; Hirata, S; Kubo, S; Maeshima, K; Saito, K; Sonomoto, K; Suzuki, K; Tanaka, Y; Yamaoka, K	1
MacFarlane, LA; Todd, DJ	1
Maneiro, JR; Salgado, E	1
So, A; Varisco, PA	1
Izumi, M; Izumi, Y; Jiuchi, Y; Kawahara, C; Kawakami, A; Kozuru, H; Migita, K; Motokawa, S; Nakamura, M; Nakamura, T; Sakai, T	1
Benda, B; Curtis, JR; Gruben, D; Komuro, Y; Lee, EB; Nakamura, H; Nduaka, CI; Riese, RJ; Silverfield, J; Soma, K; Wang, L; Wollenhaupt, J; Wood, SP; Zwillich, SH	1
Ikari, K; Inoue, E; Ishida, O; Koenuma, N; Koyama, T; Momohara, S; Ochi, K; Sakuma, Y; Taniguchi, A; Yamanaka, H; Yano, K; Yoshida, S	1
Dewenter, M; Döker, S; El-Armouche, A	1
Minota, S	1
Bradley, JD; Fleischmann, R; Gruben, D; Hall, S; Koncz, T; Krishnaswami, S; Lee, EB; van Vollenhoven, RF; Wallenstein, GV; Wilkinson, B; Zang, C; Zwillich, SH	1
Chew, R; Kawabata, T; Krishnaswami, S; Mortensen, E; Riese, R; Valdez, H; Winthrop, KL; Yamanaka, H	1
Benda, B; Cohen, S; Gomez-Reino, JJ; Krishnaswami, S; Kwok, K; Nduaka, CI; Radominski, SC; Riese, R; Soma, K; Valdez, H; Wang, L; Wood, SP	1
Kalra, S; Kaur, K; Kaushal, S	1
Boy, MG; Hutmacher, MM; Isaacs, JD; Kowalski, K; Krishnaswami, S; Lan, S; Menon, S; Nduaka, C; Riese, R; Zuckerman, A	1
Burmester, GR; Gruben, D; Mebus, CA; Strand, V; Wallenstein, GV; Zerbini, CA; Zwillich, SH	1
Kwok, SK	1
Bae, SC; Lee, YH; Song, GG	2
Krishnaswami, S; van Vollenhoven, RF; Wilkinson, B	1
Sexton, D	1
Chen, J; Xu, A; Yuan, K	1
Carmona, L; Gómez-Reino, JJ; Maneiro, JR; Mera, A; Salgado, E; Souto, A	1
Boyle, DL; Bradley, J; Firestein, GS; Hodge, J; Kaplan, I; Kavanaugh, A; Krishnaswami, S; Luo, Z; Mandel, D; Mease, P; Rosengren, S; Shurmur, R; Singhal, AK; Soma, K; Wei, N	1
Beysen, C; Charles-Schoeman, C; Davignon, J; Fleischmann, R; Hellerstein, MK; Kaplan, IV; Luo, Z; McInnes, IB; Milad, M; Riese, R; Schwartz, H; Turner, SM; Zuckerman, A	1
Nakamura, H; Takeuchi, T; Tanaka, Y; Toyoizumi, S; Yamanaka, H; Zwillich, S	1
Emery, P	1
Tanaka, Y; Zwillich, SH	1
Collins, FS; Davis, SR; Erdos, MR; Furumoto, Y; Gadina, M; Jiang, K; Kanno, Y; O'Shea, JJ; Parker, SC; Restifo, NP; Roychoudhuri, R; Ruan, Y; Sartorelli, V; Tang, Z; Vahedi, G	1
Bingham, CO; Fan, H; Gomez-Reino, J; Hodge, J; Hrycaj, P; Lee, EB; Mebus, C; Neal, J; Racewicz, A; Silverfield, J; Soma, K; Wang, T; Wilkinson, B; Winthrop, KL	1
Bukowski, J; Hammond, C; Isaacs, JD; Kivitz, AJ; Kremer, JM; Lee, SK; Li, H; Nasonov, EL; Raber, S; Schulman, SL; Simon-Campos, JA; Tony, HP; Vlahos, B; Zuckerman, A	1
Aungier, SR; Cartwright, AJ; Ito, K; Midwood, KS; To, WS	1
Benda, B; Curtis, JR; Geier, J; Kaplan, IV; Kwok, K; Lee, EB; Riese, R; Soma, K; Wang, L	1
Tanaka, Y	3
Byun, JH; Ko, SK; Lee, EK; Lee, MY; Lee, SM; Park, SK; Park, SY	1
Bananis, E; Burmester, G; Charles-Schoeman, C; Fleischmann, R; Hendrikx, T; Kwok, K; Nash, P; Soma, K; Zerbini, CA	1
Cardiel, MH; Gomez-Reino, JJ; Gul, A; Kwok, K; Lukic, T; Mortensen, E; Park, SH; Ponce de Leon, D; Riese, R; Tanaka, Y; Valdez, H; Winthrop, KL	1
Connell, C; Fleischmann, R; Gruben, D; Kanik, KS; Kremer, J; Strand, V; Wallenstein, G; Zwillich, SH	1
Abbott, B; Weatherspoon, CA; Weatherspoon, D	1
Cendón, C; Chang, HD; Di Ceglie, I; Douni, E; Gómez, L; Kamradt, T; Llop-Guevara, A; Madarena, F; Porras, M; Rinotas, V; Román, J; Siracusa, F; van Lent, PL	1
Ahadieh, S; Boy, M; Checchio, T; French, J; Geier, J; Gómez-Reino, JJ; Hoffman, E; Krishnaswami, S; Menon, S; Riese, R; Strand, V; Tensfeldt, TG	1
Hirose, T; Morishima, Y; Sugiyama, N; Takeuchi, T; Tanaka, Y; Toyoizumi, S; Yamanaka, H; Yuasa, H; Zwillich, S	1
Fleischmann, R; Gruben, D; Koncz, T; Lee, EB; Strand, V; van Vollenhoven, RF; Wallenstein, G; Wilkinson, B; Zwillich, SH	1
Bowes, MA; Bradley, JD; Conaghan, PG; Fuerst, T; Hrycaj, P; Irazoque-Palazuelos, F; Soma, K; Soto-Raices, O; van der Heijde, D; Wilkinson, B; Wu, C; Wyman, BT; Xie, Z; Zhang, R; Østergaard, M	1
Boy, M; Charles-Schoeman, C; Geier, J; Gonzalez-Gay, MA; Kaplan, I; Luo, Z; Riese, R; Zuckerman, A	1
Curtis, JR; Gerber, R; Gruben, D; Harnett, J; Koenig, A	1
Bernatsky, S; Curtis, JR; Winthrop, KL; Xie, F; Yun, H	1
Sonomoto, K; Tanaka, Y	1
Archer, TP; Ghosh, S; Moran, GW	1
Christensen, R; Hossain, A; Kotb, A; Maxwell, LJ; Mudano, AS; Shah, NP; Singh, JA; Tanjong Ghogomu, E; Tugwell, P; Wells, GA	1
Bernatsky, S; Curtis, JR; Xie, F; Yun, H	1
Iwata, S; Tanaka, Y	1
Chen, Y; Clowse, ME; Feldman, SR; Frazier, D; Geier, J; Isaacs, JD; Kimball, AB; Marren, A; Proulx, J; Strand, V; Warren, RB; Xibillé, D	1
Kawahito, Y	1
Biswas, P; Genovese, MC; Gruben, D; Jones, TV; Riese, R; Takiya, L; van Vollenhoven, RF; Wang, L; Wilkinson, B; Zwillich, SH	1
Boy, M; Charles-Schoeman, C; Geier, J; Gonzalez-Gay, MA; Kwok, K; Riese, R; Soma, K; Wicker, P; Zuckerman, A	1
Fleischmann, R; Gruben, D; Kanik, K; Keystone, E; Koncz, T; Kremer, J; Krishnaswami, S; Tanaka, Y; Wallenstein, G; Wilkinson, B; Zwillich, SH	1
Anisfeld, A; Chen, C; Chen, Y; Curtis, JR; Geier, J; Krishnaswami, S; Strengholt, S; Zhang, R	1
Gruben, D; Kremer, JM; Krishnaswami, S; Strand, V; Wallenstein, GV; Zwillich, SH	1
Iwata, S; Kubo, S; Nakayamada, S; Tanaka, Y	1
Bourret, JA; Claxton, L; Gerber, RA; Jenks, M; Mendelsohn, AM; Moynagh, D; Singh, A; Taylor, M; Wallenstein, G	1
Fukui, S; Horai, Y; Ichinose, K; Iwamoto, N; Kawakami, A; Kawashiri, SY; Koga, T; Nakamura, H; Sato, T; Umeda, M	1
Lam, S	1
Bananis, E; Connell, CA; Fleischmann, R; Hwang, LJ; Mease, PJ; Schwartzman, S; Soma, K; Takiya, L	1
Bannert, B; Erlacher, M; Fischer, K; Janowska, I; Kunze, M; Kyburz, D; Lorenzetti, R; Rizzi, M; Staniek, J; Strohmeier, V; Thiel, J; Troilo, A; Venhoff, N; Voll, RE	1
Hossain, A; Mudano, AS; Singh, JA; Tanjong Ghogomu, E; Tugwell, P; Wells, GA	1
Chen, C; Gerber, R; Gruben, D; Harnett, J; Koenig, AS	1
Jansen, JP; Smiechowski, B; Spurden, D; Vieira, MC; Wallenstein, GV; Zwillich, SH	1
Cohen, SB; Sivaraman, P	1
Aletaha, D; Gruben, D; Krishnaswami, S; Mebus, C; Smolen, JS; Zwillich, SH	1
Bliddal, H; Boers, M; Brock, B; Christensen, R; Dossing, A; Eric Furst, D; Heller Asmussen, K; Luta, G; Schjødt Jørgensen, T; Tarp, S; Tarp, U; Thirstrup, S	1
DeMasi, R; Kwok, K; Nduaka, C; Schulze-Koops, H; Strand, V; Wallenstein, G; Wang, L	1
Frank-Bertoncelj, M; Gay, S	1
Charles-Schoeman, C; Cohen, SB; Curtis, JR; DeMasi, R; Geier, J; Kwok, K; Lee, EB; Mariette, X; Nash, P; Riese, R; Tanaka, Y; Thirunavukkarasu, K; Wang, L; Winthrop, KL; Wollenhaupt, J	1
Alvarez-Moreno, C; Cardiel, MH; Castañeda, OM; Castelli, G; Citera, G; García, EG; Jaller, JJ; Kwok, K; Mysler, E; Ponce de Leon, D; Radominski, SC; Rillo, O; Rojo, R; Romero, FJ; Salinas, A	1
Danese, S; Olivera, P; Peyrin-Biroulet, L	1
Chen, L; Coe, J; Curtis, JR; Gal-Levy, R; Higginbotham, P; Nowell, WB; O'Hara, K; Sa'adon, R; Safford, M; Willig, J	1
Avaragolla, S; Bala, M; Bhalerao, A; Bhuniya, D; De, S; Dhanave, A; Hariharan, N; Jain, V; Joshi, S; Kaduskar, R; Kulkarni, B; Kurhade, S; Madgula, V; Mavinahalli, J; Mengawade, T; Mookhtiar, KA; Nadeem, A; Naik, K; Pathade, V; Petla, R; Raje, AA; Ray, S; Rouduri, S; Salunkhe, V; Tambe, A; Thakkar, M; Umrani, D	1
Buchbinder, R; Hossain, A; Lopez-Olivo, MA; Maxwell, LJ; Mudano, AS; Singh, JA; Suarez-Almazor, ME; Tanjong Ghogomu, E; Tugwell, P; Wells, GA	1
Gomez-Reino, JJ; Maneiro, JR; Souto, A	1
Gharaibeh, M; Incerti, D; Jansen, JP; Kaur, P; MacEwan, JP; Mutebi, A; Peneva, D; Stolshek, B; Strand, V	1
Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W	1
Feifel, R; Hawtin, S; Heng, R; Huppertz, C; Koch, G; Moebitz, H; Revesz, L; Scheufler, C; Schlapbach, A; Velcicky, J; Waelchli, R	1
Kukhrchuk, VV; Nasonov, EL; Novikova, DS; Popkova, TV; Tutunov, VS	1
Blaschke, S; Guerluek, S; Klinger, HM; Müller, GA; Schwarz, G; Viereck, V	1
Kameda, H; Takeuchi, T	1
Hayashi, T; Sumida, T	1
West, K	1
Bloom, BJ; Breedveld, FC; Burgos-Vargas, R; Coombs, JH; Fletcher, MP; Gruben, D; Kremer, JM; Krishnaswami, S; Wilkinson, B; Zerbini, CA; Zwillich, SH	1
Bloom, BJ; Breedveld, FC; Burgos-Vargas, R; Coombs, JH; Fletcher, MP; Gruben, D; Kremer, JM; Wilkinson, B; Zerbini, CA; Zwillich, SH	1
Hutcheson, J; Perlman, H	1
Nikitina, NM; Rebrov, AP	1
French, J; Friberg, LE; Gupta, P; Karlsson, MO; Krishnaswami, S	1
Chow, V; Cohen, S; Labadie, RR; Wilkinson, B; Zwillich, SH	1
Opar, A	1
Ginsberg, MS; Molina, AM; Motzer, RJ	1
Kremer, J; Krishnaswami, S; Riese, RJ	1
Barrish, JC; Dodd, JH; Doweyko, AM; Dyckman, AJ; Gillooly, KM; Hynes, J; Kiefer, SE; Kish, KF; Leftheris, K; Li, T; Lin, J; Lin, S; Liu, C; Marathe, PH; McIntyre, KW; McKinnon, M; Newitt, JA; Pitt, S; Sack, JS; Salter-Cid, L; Schieven, GL; Shen, DR; Shuster, DJ; Wityak, J; Wrobleski, ST; Wu, H; Zhang, H; Zhang, RF	1
Holme, I; Kvien, TK; Pedersen, TR; Semb, AG	1
El-Barbary, AM; Hamouda, HE; Hussein, MS; Ismail, RG; Rageh, EM; Wagih, AA	1
Cheng, X; Ding, YJ; Du, R; Jevallee, H; Liao, MY; Liao, YH; Shi, GP; Song, Y; Tang, TT; Xiao, H; Yao, R; Yu, X; Yuan, J; Zhou, ZH	1
French, JL; Hutmacher, MM; Krishnaswami, S; Menon, S	1
John, H; Kitas, GD; Toms, TE	1
Ishibashi, H; Izumi, Y; Jiuchi, Y; Komori, A; Maeda, Y; Migita, K; Miyashita, T; Motokawa, S; Nakamura, M; Torigoshi, T	1
Garber, K	2
French, J; Gruben, D; Tan, H; Thomas, N	1
Ishibashi, H; Izumi, Y; Jiuchi, Y; Kawakami, A; Koga, T; Komori, A; Maeda, Y; Migita, K; Miyashita, T; Motokawa, S; Nakamura, M; Sato, J; Torigoshi, T; Yamasaki, S	1
Aiba, Y; Ishibashi, H; Izumi, Y; Jiuchi, Y; Kawakami, A; Koga, T; Komori, A; Maeda, Y; Migita, K; Miyashita, T; Nakamura, M; Yamasaki, S	1
Asakawa, M; Chiba, K; Kawasumi, M; Kobayashi, T; Miyamoto, T; Mori, T; Morioka, H; Toyama, Y; Yoshida, H; Yoshimura, A	1
Connell, CA; Cutolo, M; Fleischmann, R; Genovese, MC; Gruben, D; Kanik, KS; Krishnaswami, S; Lee, EB; Sadis, S; Wallenstein, G; Wilkinson, BE; Zwillich, SH	1
Cohen, S; Connell, CA; French, JL; Gomez-Reino, J; Gruben, D; Kanik, KS; Kremer, JM; Krishnaswami, S; Pascual-Ramos, V; Wallenstein, G; Wilkinson, BE; Zwillich, SH	1
Regens, AL; Yazici, Y	1
Boyle, DL; Corr, M; Firestein, GS; Rosengren, S	1
Ohtsuka, T	1
Maeshima, K; Maeshima, Y; Tanaka, Y; Yamaoka, K	1
Kubo, S; Maeshima, K; Sonomoto, K; Tanaka, Y; Yamaoka, K	1
Lomonte, AB; Zerbini, CA	1
Leonardi, CL	1
Bradley, JD; Connell, CA; Cush, J; Fleischmann, R; Gruben, D; Kanik, KS; Kremer, J; Schulze-Koops, H; Wallenstein, GV; Zwillich, SH	1
Bradley, JD; Cohen, S; Fleischmann, R; Forejtova, S; García Meijide, JA; Gruben, D; Koncz, T; Krishnaswami, S; Lee, EB; van Vollenhoven, RF; Wagner, S; Wallenstein, GV; Wilkinson, B; Zwillich, SH	1
Fox, DA	1
Choi, J; Kim, JY; Lee, EB; Lee, EY; Lee, YJ; Song, YW; Yoo, HJ	1
de Lartigue, J	1
Chan, C; Ivashkiv, LB; Xu, K; Yarilina, A	1
Heinzl, S	1
Traynor, K	1
Steiger, B; Yazici, Y	1
Miossec, P	1
Benda, B; Blanco, R; Bradley, J; Burmester, GR; Charles-Schoeman, C; Gruben, D; Koncz, T; Krishnaswami, S; Mebus, C; Soma, K; Wallenstein, G; Wollenhaupt, J; Zerbini, C; Zwillich, SH	1
van Vollenhoven, RF	1
Benda, B; Bradley, JD; Cardiel, MH; Cohen, S; Connell, CA; Fleischmann, R; Gruben, D; Keystone, E; Kremer, J; Krishnaswami, S; Nash, P; Song, YW; Tanaka, Y; Tegzová, D; van der Heijde, D; Wallenstein, G; Wyman, BT; Zerbini, C; Zwillich, SH	1
Reinke, T	1
Burmester, GR; Feist, E	1
Hamsten, A; Klareskog, L	1
Capell, HA; Ford, I; Hampson, R; Madhok, R; McCarey, DW; McInnes, IB; Sattar, N; Scherbakov, O	1
McColl, G; Van Doornum, S; Wicks, IP	1
Abe, K; Akasaka, Y; Inoue, H; Sato, T	1
Harten, SK; Haskard, DO; Johns, M; Kinderlerer, AR; Lidington, EA; Mason, JC; Maxwell, PH; Steinberg, R	1
Jansen, TL	1
de Vegvar, HE; Digennaro, C; Higgins, JP; Ho, PP; Kidd, BA; Lee, LY; Robinson, WH; Steinman, L; Tomooka, B	1
Hampton, T	1
Ansell, BJ; Charles-Schoeman, C; Fogelman, AM; Furst, DE; Gong, T; Khanna, D; McMahon, M; Park, GS; Paulus, HE; Reddy, ST	1
Gay, RE; Gay, S; Kurowska-Stolarska, M; Laufer, S; Michel, BA; Neidhart, M; Ospelt, C	1
Bielinska, A; Gluszko, P	1
Changelian, PS; Doty, JL; Flanagan, ME; Harris, TM; Kent, CR; Kudlacz, EM; Kuhn, CF; Magnuson, KS; Moshinsky, D; Munchhof, MJ; Perregaux, DG; Sawyer, PS; Sun, J; Whipple, DA	1
Audoly, L; Changelian, P; Kudlacz, EM; Milici, AJ; Zwillich, S	1
O'Brien, WM	1
Fellmann, N	1
Gumpel, JM; Prouse, PJ; Wilson, AP	1
Levy, J	1
di Munno, O; Sarchi, C	1
Ehrlich, GE	1
Desiraju, RK; Dromgoole, SH; Furst, DE; Paulus, HE	1
Balme, HW; Huskisson, EC; Wojtulewski, JA	1
Grindel, JM	1
Desiraju, RK; Dromgoole, SH; Furst, DE; Kirschenbaum, MA; Nayak, RK; Paulus, HE	1
Desiraju, RK; Ng, KT; Sedberry, DC	1
Chatterjee, GP	1
Chabot-Fletcher, M; Jackson, JR; Marshall, LA; Roshak, A	1
Gay, RE; Gay, S; Laufer, S; Neidhart, M; Pataky, F; Tries, S	1
Cordrey, LJ	1
Lewis, JR	1
Iwasaki, Y; Onoda, D; Shiokawa, Y; Yamamoto, M	1
Perrotta, P; Silvestri, N	1
Klemp, P; Meyers, OL	1
Avery, GS; Brogden, RN; Heel, RC; Speight, TM	1
Ansell, BM; Carter, ME; Gumpel, JM; Meanock, I; Rosenburg, J; Steele, CE	1
DeGuzmann, R; Gabovitch, E; Love, DW; Saykaly, RJ; Simon, JA	1
Davis, JD; Pisko, EJ; Ruchte, IR; Struth, AG; Turner, RA	1
Miller, JL	1
Grindel, JM; Migdalof, BH; Plostnieks, J	1
Pavelka, K; Susta, A	2
Brown, JR; Weir, AB	1
Scherbel, AL	1
Joseph, MW; Sakai, J	1
Paulus, HE; Restivo, C	1
Madsen, BW; Selley, ML; Thomas, J	1
Aylward, M; Holly, F; Maddock, J; Parker, RJ; Thomas, SR	1
Fostiropoulos, G	1
Remans, J	2
Vetter, G	2
Viara, M	1
Dequeker, J; Goddeeris, T	1
Carrington, MD; de Salcedo, I; Lemos, MM; Silva, JL	1
Commandre, F; Viani, JL	1
Arramon, JY; Laborie, G	1
Maibach, E	1
Zarro, VJ	1
Bain, LS; Collins, RM; el-Ghobarey, AF; Sargent, NW	1
Bachmann, F; Hartl, W; Stroescu, O	1
Bonus, L; Gum, OB; Maggio-Cavaliere, MB	1
Glass, J; Selley, ML; Thomas, J; Triggs, EJ	1
Biland, L; Duckert, F; Nyman, D; Rüst, O; Thilo, D	1
Bastin, JM	1
Gillet, C; Lamberlin, G; Roba, J; Roncucci, R	1
Biltris, R; Delmeiren, H; Desproges-Gotteron, R; Diverse, P; Gerard, R; Golstein, M; Le Guen, A; Vetter, G; Viara, M	1
Adair, SF; Bird, HA; Bojar, R; Catalano, MA; Dixon, JS; Hill, J; Liauw, L; Rotman, H; Sussman, H; Traficante, A	1
Goehrs, HR; Sagraves, R; Waller, ES	1
Berkowitz, SS; Bernhard, G; Bilka, PJ; Blechman, WJ; Marchesano, JM; Rosenthal, M; Wortham, GF	1
Brooks, PM; Lee, P; Sturrock, RD; Watkins, CF	1
Gardocki, JF; Pruss, TP; Wong, S	1
Campos, V; Evans, EF; Pollack, D; Proctor, JD; Velandia, J; Wasserman, AJ; Wingfield, WL	1
Balme, HW; Berry, H; Huskisson, EC; Scott, J	1
Johansson, SV; Strandberg, PO	1
Iizuka, Y; Masuda, H; Tanaka, K; Tomita, K; Yoshida, N	1

Reviews

108 review(s) available for pyrroles and Arthritis, Rheumatoid

Article	Year
Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination. Clinical and experimental rheumatology, 2022, Volume: 40, Issue:7 Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Colitis, Ulcerative; Gastroenterology; Herpes Zoster; Humans; Janus Kinase Inhibitors; Janus Kinases; Pyrroles; Rheumatology; Vaccination	2022
Oral surveillance and JAK inhibitor safety: the theory of relativity. Nature reviews. Rheumatology, 2022, Volume: 18, Issue:5 Topics: Aged; Arthritis, Rheumatoid; Humans; Janus Kinase Inhibitors; Pyrroles; Tumor Necrosis Factor Inhibitors	2022
Real-world evidence of tofacitinib in rheumatoid arthritis patients in Spain. Drug discoveries & therapeutics, 2022, May-17, Volume: 16, Issue:2 Topics: Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Spain; Treatment Outcome	2022
The Proportion of Patients With Rheumatoid Arthritis Achieving ACR20/50/70; Consistent Patterns of a 60/40/20 as Demonstrated by a Systematic Review and Meta-analysis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2023, Jun-01, Volume: 29, Issue:4 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Humans; Methotrexate; Pyrroles; Treatment Outcome	2023
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs. Alimentary pharmacology & therapeutics, 2023, Volume: 57, Issue:11 Topics: Arthritis, Rheumatoid; Bradycardia; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Pyrroles	2023
[Role of janus kinase inhibitors in the treatment of rheumatic diseases]. Der Internist, 2019, Volume: 60, Issue:11 Topics: Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Drug Therapy, Combination; Humans; Janus Kinase Inhibitors; Methotrexate; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome	2019
Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis. Rheumatology (Oxford, England), 2019, 11-01, Volume: 58, Issue:Suppl 5 Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Biological Products; Fatigue; Humans; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides	2019
Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Zeitschrift fur Rheumatologie, 2020, Volume: 79, Issue:6 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Humans; Methotrexate; Network Meta-Analysis; Piperidines; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles	2020
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. Gastroenterology, 2020, Volume: 158, Issue:6 Topics: Arthritis, Rheumatoid; Azetidines; Herpes Zoster; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Janus Kinases; Piperidines; Placebos; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Spondylitis, Ankylosing; Sulfonamides; Survival Analysis; Treatment Outcome; Triazoles	2020
Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement. Clinical rheumatology, 2020, Volume: 39, Issue:3 Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Bone and Bones; Bone Remodeling; Humans; Immune System; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors	2020
Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis. Advances in therapy, 2020, Volume: 37, Issue:5 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Methotrexate; Network Meta-Analysis; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Sulfonamides	2020
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs. Zeitschrift fur Rheumatologie, 2021, Volume: 80, Issue:4 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Biological Products; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles	2021
JAK inhibitors for the treatment of rheumatoid arthritis. Immunological medicine, 2020, Volume: 43, Issue:4 Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Benzofurans; Cardiovascular Diseases; Herpes Zoster; Humans; Janus Kinases; Molecular Targeted Therapy; Neutropenia; Niacinamide; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Venous Thromboembolism	2020
A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies. Dermatology online journal, 2020, Mar-15, Volume: 26, Issue:3 Topics: Adult; Arthritis, Rheumatoid; Female; Hidradenitis Suppurativa; Humans; Janus Kinase Inhibitors; Keratoacanthoma; Melanoma; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Psoriasis; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha; Vitiligo	2020
Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China. PharmacoEconomics, 2020, Volume: 38, Issue:12 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; China; Cost-Benefit Analysis; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Treatment Outcome	2020
Comparison of the efficacy and safety of tofacitinib and mavrilimumab in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials. International journal of clinical pharmacology and therapeutics, 2021, Volume: 59, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome	2021
Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis. Rheumatology (Oxford, England), 2021, 05-05, Volume: 60, Issue:Suppl 2 Topics: Acetonitriles; Arthritis, Rheumatoid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Triazoles	2021
Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis. Skin therapy letter, 2017, Volume: 22, Issue:2 Topics: Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome	2017
Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the rheumatic diseases, 2017, Volume: 76, Issue:6 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Drug Therapy, Combination; Glucocorticoids; Humans; Methotrexate; Piperidines; Practice Guidelines as Topic; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides	2017
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. The Cochrane database of systematic reviews, 2017, 05-08, Volume: 5 Topics: Abatacept; Adalimumab; Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Products; Etanercept; Humans; Infliximab; Methotrexate; Methylprednisolone; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rituximab	2017
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. The Journal of arthroplasty, 2017, Volume: 32, Issue:9 Topics: Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Elective Surgical Procedures; Glucocorticoids; Humans; Lupus Erythematosus, Systemic; Perioperative Care; Piperidines; Pyrimidines; Pyrroles; Rheumatic Diseases; Rheumatology; Spondylarthritis; Spondylitis, Ankylosing; Surgeons; United States	2017
Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis. Clinical therapeutics, 2017, Volume: 39, Issue:8 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Humans; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Tumor Necrosis Factor-alpha	2017
A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate. Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:14 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Janus Kinase Inhibitors; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome	2017
Two new drugs for rheumatoid arthritis. Drug and therapeutics bulletin, 2017, Volume: 55, Issue:9 Topics: Arthritis, Rheumatoid; Azetidines; Humans; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides	2017
Tofacitinib in the treatment of active rheumatoid arthritis in adults. Immunotherapy, 2018, Volume: 10, Issue:1 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Humans; Janus Kinases; Molecular Targeted Therapy; Piperidines; Pyrimidines; Pyrroles	2018
[Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis]. Ugeskrift for laeger, 2017, Oct-30, Volume: 179, Issue:44 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Herpes Zoster; Humans; Janus Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides	2017
Tofacitinib: A Review in Rheumatoid Arthritis. Drugs, 2017, Volume: 77, Issue:18 Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Janus Kinases; Methotrexate; Piperidines; Pyrimidines; Pyrroles	2017
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk? Drug safety, 2018, Volume: 41, Issue:7 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Humans; Janus Kinase Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Risk Factors; Sulfonamides; Thromboembolism	2018
Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 2018, Volume: 36, Issue:9 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Drug Costs; Drug Resistance; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Technology Assessment, Biomedical	2018
Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2019, Volume: 25, Issue:3 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Humans; Janus Kinase Inhibitors; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2019
[Research progress of JAK-3 kinase and its inhibitors]. Yao xue xue bao = Acta pharmaceutica Sinica, 2016, Volume: 51, Issue:10 Topics: Arthritis, Rheumatoid; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles	2016
Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. Expert review of clinical immunology, 2018, Volume: 14, Issue:11 Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Humans; Janus Kinase 1; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides	2018
Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Zeitschrift fur Rheumatologie, 2019, Volume: 78, Issue:6 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Humans; Network Meta-Analysis; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides	2019
Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford, England), 2019, 06-01, Volume: 58, Issue:6 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Humans; Inflammation; Janus Kinase Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides	2019
A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis. Clinical rheumatology, 2019, Volume: 38, Issue:5 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Factors; Drug Therapy, Combination; Etanercept; Humans; Infliximab; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rituximab; Treatment Outcome	2019
Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis. Immunotherapy, 2019, Volume: 11, Issue:4 Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Asia, Eastern; Drug Therapy, Combination; Herpes Zoster; Herpesvirus 3, Human; Humans; Mycobacterium tuberculosis; Piperidines; Prevalence; Pyrimidines; Pyrroles; Recurrence; Risk; Tuberculosis; Virus Activation	2019
Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients. Journal of clinical pharmacy and therapeutics, 2019, Volume: 44, Issue:3 Topics: Arthritis, Rheumatoid; Biological Products; Humans; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic	2019
Clinical efficacy of new JAK inhibitors under development. Just more of the same? Rheumatology (Oxford, England), 2019, 02-01, Volume: 58, Issue:Suppl 1 Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase 3; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles; Valine	2019
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford, England), 2019, 02-01, Volume: 58, Issue:Suppl 1 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Drug Therapy, Combination; Humans; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Janus Kinase Inhibitors; Methotrexate; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome	2019
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford, England), 2019, 10-01, Volume: 58, Issue:10 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Herpes Zoster; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Infections; Janus Kinase Inhibitors; Male; Middle Aged; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides	2019
Tofacitinib for the treatment of rheumatoid arthritis: an update. Expert review of clinical immunology, 2019, Volume: 15, Issue:6 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles	2019
JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis. Expert review of clinical pharmacology, 2019, Volume: 12, Issue:6 Topics: Adamantane; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Proliferation; Humans; Janus Kinase 3; Janus Kinase Inhibitors; Methotrexate; Niacinamide; Piperidines; Pyrimidines; Pyrroles	2019
[JAK Inhibitors in Rheumatology]. Deutsche medizinische Wochenschrift (1946), 2019, Volume: 144, Issue:11 Topics: Arthritis, Rheumatoid; Azetidines; Germany; Humans; Janus Kinase Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides	2019
Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials. International journal of rheumatic diseases, 2019, Volume: 22, Issue:8 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome	2019
A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:6 Topics: Administration, Oral; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Cytochrome P-450 CYP3A; Humans; Janus Kinase 1; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles	2013
Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment. Current drug targets, 2013, Volume: 14, Issue:12 Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Inflammatory Bowel Diseases; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; United States; United States Food and Drug Administration	2013
Tofacitinib: a review of its use in adult patients with rheumatoid arthritis. Drugs, 2013, Volume: 73, Issue:8 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2013
The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clinical rheumatology, 2013, Volume: 32, Issue:10 Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Inflammation; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Treatment Outcome; Tumor Necrosis Factor-alpha	2013
Tofacitinib for treatment of rheumatoid arthritis. Advances in therapy, 2013, Volume: 30, Issue:8 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2013
[JAK inhibitor]. Nihon rinsho. Japanese journal of clinical medicine, 2013, Volume: 71, Issue:7 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction	2013
Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC musculoskeletal disorders, 2013, Oct-18, Volume: 14 Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2013
Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles	2014
Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies. BMC musculoskeletal disorders, 2013, Nov-26, Volume: 14 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Humans; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Failure	2013
Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis. The Annals of pharmacotherapy, 2013, Volume: 47, Issue:11 Topics: Arthritis, Rheumatoid; Aryl Hydrocarbon Hydroxylases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Interactions; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2013
Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): a systematic review and meta-analysis. Clinical rheumatology, 2014, Volume: 33, Issue:2 Topics: Acute Disease; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Humans; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome	2014
Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Annals of the rheumatic diseases, 2014, Volume: 73, Issue:3 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Evidence-Based Medicine; Glucocorticoids; Humans; Methotrexate; Piperidines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome	2014
Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis. International journal of rheumatic diseases, 2014, Volume: 17, Issue:4 Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Design; Humans; Janus Kinases; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Pyrroles; Signal Transduction	2014
[New therapies for rheumatoid arthritis]. Medicina clinica, 2014, Nov-18, Volume: 143, Issue:10 Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Piperidines; Pyrimidines; Pyrroles; Rituximab; Treatment Outcome; Tumor Necrosis Factor-alpha	2014
Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. The Journal of rheumatology, 2014, Volume: 41, Issue:5 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Janus Kinase 3; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles	2014
[Tofacitinib]. Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:19 Topics: Administration, Oral; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Drug Approval; Europe; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2014
Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis & rheumatology (Hoboken, N.J.), 2014, Volume: 66, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Infections; Longitudinal Studies; Male; Methotrexate; Middle Aged; Piperidines; Prevalence; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome; Young Adult	2014
Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis. Clinical therapeutics, 2014, Jul-01, Volume: 36, Issue:7 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2014
Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials. The Korean journal of internal medicine, 2014, Volume: 29, Issue:5 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Janus Kinases; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome	2014
Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis & rheumatology (Hoboken, N.J.), 2015, Volume: 67, Issue:1 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Biological Products; Chronic Disease; Female; Humans; Lipids; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Spondylarthritis; Treatment Outcome	2015
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Annals of the rheumatic diseases, 2016, Volume: 75, Issue:5 Topics: Administration, Oral; Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Female; Humans; Incidence; Janus Kinase 3; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Young Adult	2016
Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Rheumatology international, 2015, Volume: 35, Issue:12 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome	2015
Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside. Journal of biochemistry, 2015, Volume: 158, Issue:3 Topics: Arthritis, Rheumatoid; Humans; Inflammation; Janus Kinase 1; Janus Kinase 3; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; STAT1 Transcription Factor; Translational Research, Biomedical; Tumor Necrosis Factor-alpha	2015
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Annals of the rheumatic diseases, 2016, Volume: 75, Issue:6 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Immunocompromised Host; Immunosuppressive Agents; Incidence; Janus Kinase 3; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Assessment; Tuberculosis	2016
Pharmacology Update on Chronic Obstructive Pulmonary Disease, Rheumatoid Arthritis, and Major Depression. The Nursing clinics of North America, 2015, Volume: 50, Issue:4 Topics: Anti-Anxiety Agents; Arthritis, Rheumatoid; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Depressive Disorder; Fluticasone; Humans; Nursing Process; Piperazines; Piperidines; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyrimidines; Pyrroles; Sulfides; United States; Vortioxetine	2015
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis research & therapy, 2015, Dec-15, Volume: 17 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Communicable Diseases; Humans; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome	2015
Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled tri International journal of rheumatic diseases, 2016, Volume: 19, Issue:11 Topics: Abatacept; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Products; Drug Substitution; Humans; Network Meta-Analysis; Odds Ratio; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rituximab; Treatment Failure; Tumor Necrosis Factor-alpha	2016
Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Seminars in arthritis and rheumatism, 2016, Volume: 46, Issue:1 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Lipids; Piperidines; Pyrimidines; Pyrroles; Rheumatology	2016
Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis. Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 2015, Volume: 38, Issue:6 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Herpes Zoster; Humans; Janus Kinases; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocyte Subsets	2015
Tofacitinib in ulcerative colitis. Immunotherapy, 2016, Volume: 8, Issue:5 Topics: Animals; Arthritis, Rheumatoid; Autoimmunity; Colitis, Ulcerative; Cytokines; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction	2016
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. The Cochrane database of systematic reviews, 2016, May-13, Issue:5 Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Etanercept; Humans; Infliximab; Interleukin 1 Receptor Antagonist Protein; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rituximab	2016
Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster. Drug safety, 2016, Volume: 39, Issue:9 Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Herpes Zoster; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles	2016
Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. Expert review of clinical immunology, 2016, Volume: 12, Issue:10 Topics: Administration, Oral; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Heterocyclic Compounds, 2-Ring; Humans; Janus Kinase 1; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Valine	2016
[Guidelines for the management of rheumatoid arthritis]. Nihon rinsho. Japanese journal of clinical medicine, 2016, Volume: 74, Issue:6 Topics: Abatacept; Algorithms; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Substitution; Drug Therapy, Combination; Humans; Japan; Methotrexate; Piperidines; Practice Guidelines as Topic; Pyrimidines; Pyrroles	2016
[Tofacitinib for the treatment of rheumatoid arthritis]. Nihon rinsho. Japanese journal of clinical medicine, 2016, Volume: 74, Issue:6 Topics: Administration, Ophthalmic; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Drug Discovery; Humans; Janus Kinases; Lymphocytes; Molecular Targeted Therapy; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Sulfonamides; Treatment Outcome	2016
Relation between disease modifying anti-rheumatic drugs and herpes zoster in rheumatoid arthritis. Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 2016, Volume: 39, Issue:3 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Follow-Up Studies; Herpes Zoster; Humans; Incidence; Janus Kinases; Japan; Molecular Targeted Therapy; Piperidines; Product Surveillance, Postmarketing; Pyrimidines; Pyrroles	2016
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. International journal of rheumatic diseases, 2016, Volume: 19, Issue:12 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Janus Kinases; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome	2016
Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2016, Volume: 30, Issue:5 Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinases; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles	2016
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). The Cochrane database of systematic reviews, 2016, 11-17, Volume: 11 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Disease Progression; Etanercept; Humans; Interleukin 1 Receptor Antagonist Protein; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Rituximab; Treatment Failure	2016
Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis. Clinical therapeutics, 2016, Volume: 38, Issue:12 Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Humans; Male; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Rituximab; Treatment Failure; Treatment Outcome; Tumor Necrosis Factor-alpha	2016
Malignancy and Janus Kinase Inhibition. Rheumatic diseases clinics of North America, 2017, Volume: 43, Issue:1 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Incidence; Janus Kinases; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Neoplasms	2017
Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology (Oxford, England), 2017, 03-01, Volume: 56, Issue:3 Topics: Abatacept; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Etanercept; Humans; Network Meta-Analysis; Piperidines; Poisson Distribution; Pyrimidines; Pyrroles; Regression Analysis; Risk; Rituximab	2017
JAK inhibition in inflammatory bowel disease. Expert review of clinical immunology, 2017, Volume: 13, Issue:7 Topics: Animals; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Inflammatory Bowel Diseases; Janus Kinases; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Assessment; Signal Transduction; STAT Transcription Factors	2017
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. The Cochrane database of systematic reviews, 2017, 03-10, Volume: 3 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Products; Disease Progression; Humans; Methotrexate; Neoplasms; Network Meta-Analysis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Failure	2017
Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. Seminars in arthritis and rheumatism, 2017, Volume: 47, Issue:2 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Humans; Neoplasms; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Risk	2017
[Rheumatoid arthritis]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:3 Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Autoantibodies; Cytokines; Humans; Immunoconjugates; Janus Kinase 3; Peptides, Cyclic; Piperidines; Pyrimidines; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory	2009
[Targeted therapies including monoclonal antibodies for connective tissue diseases]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:3 Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; B-Lymphocytes; Connective Tissue Diseases; Etanercept; Humans; Immunoglobulin G; Infliximab; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles; Receptors, Interleukin-6; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha	2009
CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Current opinion in investigational drugs (London, England : 2000), 2009, Volume: 10, Issue:5 Topics: Animals; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Evaluation, Preclinical; Graft Rejection; Humans; Immunosuppressive Agents; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles	2009
BH3-only proteins in rheumatoid arthritis: potential targets for therapeutic intervention. Oncogene, 2008, Volume: 27 Suppl 1 Topics: Animals; Antirheumatic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arthritis, Rheumatoid; Autoimmunity; Bcl-2-Like Protein 11; BH3 Interacting Domain Death Agonist Protein; Drug Delivery Systems; Drug Design; Gene Expression Regulation; Humans; Indoles; Macrophages; Membrane Proteins; Mice; Mice, Inbred C57BL; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Structure-Activity Relationship; T-Lymphocyte Subsets	2008
Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best practice & research. Clinical rheumatology, 2010, Volume: 24, Issue:4 Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Health Status; Humans; Janus Kinase 3; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome	2010
Rheumatoid arthritis: is it a coronary heart disease equivalent? Current opinion in cardiology, 2011, Volume: 26, Issue:4 Topics: Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Coronary Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hyperlipidemias; Pyrroles; Risk Factors	2011
Promising new treatments for rheumatoid arthritis - the kinase inhibitors. Bulletin of the NYU hospital for joint diseases, 2011, Volume: 69, Issue:3 Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Intracellular Signaling Peptides and Proteins; Janus Kinases; Morpholines; Oxazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Syk Kinase; Treatment Outcome	2011
[Recent progress in the treatment of rheumatoid arthritis]. Clinical calcium, 2012, Volume: 22, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Denosumab; Etanercept; Humans; Immunoglobulin G; Infliximab; Interleukin-6; Methotrexate; Molecular Targeted Therapy; Piperidines; Pyrimidines; Pyrroles; RANK Ligand; Receptors, Tumor Necrosis Factor; Reference Standards; Remission Induction; Tumor Necrosis Factor-alpha	2012
Novel small-molecular therapeutics for rheumatoid arthritis. Current opinion in rheumatology, 2012, Volume: 24, Issue:3 Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinases; Molecular Targeted Therapy; Morpholines; Oxazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles	2012
Tofacitinib for the treatment of rheumatoid arthritis. Expert review of clinical immunology, 2012, Volume: 8, Issue:4 Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2012
[Janus kinase inhibitors as a new therapeutic principle]. Medizinische Monatsschrift fur Pharmazeuten, 2012, Volume: 35, Issue:10 Topics: Arthritis, Rheumatoid; Colitis, Ulcerative; Enzyme Inhibitors; Humans; Janus Kinases; Nitriles; Piperidines; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction	2012
JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Modern rheumatology, 2013, Volume: 23, Issue:3 Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2013
Kinase inhibitors for the treatment of rheumatoid arthritis. Bulletin of the NYU hospital for joint diseases, 2012, Volume: 70, Issue:3 Topics: Aminopyridines; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Morpholines; Oxazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Signal Transduction; Treatment Outcome	2012
Tofacitinib (Xeljanz) for rheumatoid arthritis. The Medical letter on drugs and therapeutics, 2013, Jan-07, Volume: 55, Issue:1407 Topics: Animals; Arthritis, Rheumatoid; Humans; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic	2013
Rheumatoid arthritis in 2012: Progress in RA genetics, pathology and therapy. Nature reviews. Rheumatology, 2013, Volume: 9, Issue:2 Topics: Arthritis, Rheumatoid; Disease Management; Enzyme Inhibitors; Genetic Predisposition to Disease; HLA Antigens; Humans; Piperidines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles	2013
Small molecules targeting JAKs--a new approach in the treatment of rheumatoid arthritis. Rheumatology (Oxford, England), 2013, Volume: 52, Issue:8 Topics: Administration, Oral; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forecasting; Germany; Humans; Janus Kinases; Male; Maximum Tolerated Dose; Molecular Targeted Therapy; Morpholines; Oxazines; Piperidines; Prognosis; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome	2013
[Statins--are they potentially useful in rheumatology?]. Polskie Archiwum Medycyny Wewnetrznej, 2007, Volume: 117, Issue:9 Topics: Arthritis, Rheumatoid; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Osteoporosis; Pyrroles; Rheumatic Diseases; Simvastatin; Treatment Outcome	2007
The pharmacokinetic and metabolic profile of the antiinflammatory agent tolmetin in laboratory animals and man. Drug metabolism reviews, 1981, Volume: 12, Issue:2 Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Biological Availability; Guinea Pigs; Humans; Kinetics; Mice; Pyrroles; Rats; Species Specificity; Tissue Distribution; Tolmetin	1981
Tolmetin: a review of its pharmacological properties and therapeutic efficacy in rheumatic diseases. Drugs, 1978, Volume: 15, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Arthritis, Rheumatoid; Blood Platelets; Endocrine Glands; Humans; Intestinal Absorption; Intestinal Mucosa; Kinetics; Osteoarthritis; Prostaglandin Antagonists; Pyrroles; Rats; Rheumatic Diseases; Skin Tests; Spondylitis, Ankylosing; Tolmetin	1978

Trials

102 trial(s) available for pyrroles and Arthritis, Rheumatoid

Article	Year
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Annals of the rheumatic diseases, 2022, Volume: 81, Issue:6 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Tumor Necrosis Factor Inhibitors	2022
Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials. The Journal of rheumatology, 2022, Volume: 49, Issue:6 Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Rheumatology; Treatment Outcome; United States	2022
The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials. Arthritis research & therapy, 2022, 04-05, Volume: 24, Issue:1 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Fatigue; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Sleep; Treatment Outcome	2022
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. RMD open, 2022, Volume: 8, Issue:1 Topics: Adult; Arthritis, Rheumatoid; Body Mass Index; Humans; Piperidines; Pyrimidines; Pyrroles	2022
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial. Annals of the rheumatic diseases, 2022, Volume: 81, Issue:11 Topics: Analgesics, Opioid; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Female; Humans; Lung Diseases; Piperidines; Pyrimidines; Pyrroles; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha	2022
Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors. RMD open, 2022, Volume: 8, Issue:2 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Humans; Prospective Studies; Proteomics; Pyrroles; Tumor Necrosis Factor Inhibitors; Venous Thromboembolism	2022
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Annals of the rheumatic diseases, 2023, Volume: 82, Issue:3 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Lung Neoplasms; Pyrroles; Risk Factors; Skin Neoplasms; Treatment Outcome; Tumor Necrosis Factor Inhibitors	2023
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD open, 2022, Volume: 8, Issue:2 Topics: Adalimumab; Arthritis, Psoriatic; Arthritis, Rheumatoid; Bayes Theorem; C-Reactive Protein; Humans; Inflammation; Pyrroles; Treatment Outcome	2022
Continuation, reduction, or withdrawal of tofacitinib in patients with rheumatoid arthritis achieving sustained disease control: a multicenter, open-label, randomized controlled trial. Chinese medical journal, 2023, Feb-05, Volume: 136, Issue:3 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; China; Humans; Piperidines; Pyrroles; Quality of Life; Treatment Outcome	2023
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2). Annals of the rheumatic diseases, 2023, Volume: 82, Issue:12 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Double-Blind Method; Humans; Methotrexate; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome	2023
Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis. Arthritis research & therapy, 2019, 10-21, Volume: 21, Issue:1 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Piperidines; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2019
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD open, 2019, Volume: 5, Issue:2 Topics: Adalimumab; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome	2019
Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis & rheumatology (Hoboken, N.J.), 2020, Volume: 72, Issue:10 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Female; Humans; Janus Kinase 3; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2020
Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib. Arthritis research & therapy, 2020, 10-15, Volume: 22, Issue:1 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Fatigue; Humans; Pain; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2020
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD open, 2020, Volume: 6, Issue:3 Topics: Adult; Arthritis, Rheumatoid; Humans; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2020
Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials. Rheumatology (Oxford, England), 2017, 08-01, Volume: 56, Issue:8 Topics: Adalimumab; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cost of Illness; Double-Blind Method; Drug Therapy, Combination; Female; Health Expenditures; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Return to Work; Risk Factors; Treatment Outcome	2017
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet (London, England), 2017, 07-29, Volume: 390, Issue:10093 Topics: Adalimumab; Administration, Oral; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome	2017
The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial. Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:10 Topics: Aged; Antibodies, Viral; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Enzyme-Linked Immunospot Assay; Female; Herpes Zoster; Herpes Zoster Vaccine; Herpesvirus 3, Human; Humans; Immunogenicity, Vaccine; Immunoglobulin G; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocytes	2017
Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies. The Journal of rheumatology, 2018, Volume: 45, Issue:2 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Disease Progression; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Health Surveys; Humans; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2018
Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients. Internal medicine (Tokyo, Japan), 2018, Mar-01, Volume: 57, Issue:5 Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome	2018
Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial. International journal of rheumatic diseases, 2018, Volume: 21, Issue:2 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; China; Disability Evaluation; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Female; Health Status; Humans; Male; Middle Aged; Pain Measurement; Patient Reported Outcome Measures; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality of Life; Recovery of Function; Time Factors; Treatment Outcome; Young Adult	2018
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers. Clinical immunology (Orlando, Fla.), 2018, Volume: 191 Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Healthy Volunteers; Humans; Janus Kinase Inhibitors; Leukocytes; Lymphocyte Count; Male; Middle Aged; Phenotype; Piperidines; Pyrimidines; Pyrroles; T-Lymphocytes	2018
Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials. Clinical rheumatology, 2018, Volume: 37, Issue:8 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Remission Induction; Treatment Outcome	2018
Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6. Arthritis care & research, 2019, Volume: 71, Issue:1 Topics: Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Probability; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome	2019
Analysis of miRNA expression in patients with rheumatoid arthritis during remission and relapse after a 5-year trial of tofacitinib treatment. International immunopharmacology, 2018, Volume: 63 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; MicroRNAs; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Recurrence	2018
Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses. Medicine, 2018, Volume: 97, Issue:31 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Brazil; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Janus Kinase Inhibitors; Male; Methotrexate; Middle Aged; Patient Reported Outcome Measures; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2018
Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study. Rheumatology (Oxford, England), 2019, 01-01, Volume: 58, Issue:1 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Janus Kinase Inhibitors; Japan; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2019
A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population. Seminars in arthritis and rheumatism, 2018, Volume: 48, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult	2018
Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis. Chinese medical journal, 2018, Nov-20, Volume: 131, Issue:22 Topics: Administration, Oral; Adult; Aged; Arthritis, Rheumatoid; Asian People; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Surveys and Questionnaires; Young Adult	2018
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:6 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Janus Kinase Inhibitors; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2019
Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib. RMD open, 2019, Volume: 5, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anti-Citrullinated Protein Antibodies; Arthritis, Rheumatoid; Biomarkers; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Patient Reported Outcome Measures; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rheumatoid Factor; Risk Factors; Treatment Outcome; Young Adult	2019
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis research & therapy, 2019, 04-05, Volume: 21, Issue:1 Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Herpes Zoster; Humans; Male; Middle Aged; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome	2019
Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study. Arthritis care & research, 2020, Volume: 72, Issue:3 Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Herpes Zoster; Herpes Zoster Vaccine; Humans; Incidence; Janus Kinase Inhibitors; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles	2020
Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Annals of the rheumatic diseases, 2014, Volume: 73, Issue:1 Topics: Administration, Oral; Adult; Arthritis, Rheumatoid; Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Piperidines; Placebos; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2014
Tofacitinib prevents radiographic progression in rheumatoid arthritis. Journal of Korean medical science, 2013, Volume: 28, Issue:8 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disease Progression; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiography; Severity of Illness Index; Treatment Outcome	2013
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Annals of internal medicine, 2013, Aug-20, Volume: 159, Issue:4 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Remission Induction; Treatment Outcome	2013
Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. Rheumatology (Oxford, England), 2014, Volume: 53, Issue:5 Topics: Adult; Aged; Arthritis, Rheumatoid; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Count; Cell Proliferation; Double-Blind Method; Female; Humans; In Vitro Techniques; Infections; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors; Severity of Illness Index; Treatment Outcome	2014
Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis. Clinical and experimental immunology, 2014, Volume: 175, Issue:2 Topics: Adult; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Arthritis, Rheumatoid; C-Reactive Protein; Double-Blind Method; Down-Regulation; Female; Humans; Interleukin-6; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Placebos; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Interleukin-6; Serum Amyloid A Protein	2014
Tofacitinib versus methotrexate in rheumatoid arthritis. The New England journal of medicine, 2014, Jun-19, Volume: 370, Issue:25 Topics: Administration, Oral; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cholesterol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Herpes Zoster; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles	2014
Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. Arthritis research & therapy, 2014, Jul-25, Volume: 16, Issue:4 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Inflammation; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles	2014
Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial. Arthritis care & research, 2015, Volume: 67, Issue:4 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Self Report; Treatment Outcome	2015
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Annals of the rheumatic diseases, 2015, Volume: 74, Issue:6 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chemokines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinase 1; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; RNA, Messenger; Signal Transduction; STAT Transcription Factors; Synovial Membrane; Treatment Outcome	2015
Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis & rheumatology (Hoboken, N.J.), 2015, Volume: 67, Issue:3 Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Biomarkers; Cholesterol; Female; Healthy Volunteers; Humans; Hungary; Lipoproteins; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Young Adult	2015
Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Modern rheumatology, 2015, Volume: 25, Issue:4 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Female; Follow-Up Studies; Humans; Janus Kinase 3; Japan; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome	2015
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Annals of the rheumatic diseases, 2016, Volume: 75, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Influenza Vaccines; Influenza, Human; Male; Methotrexate; Middle Aged; Piperidines; Pneumococcal Infections; Pneumococcal Vaccines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Young Adult	2016
Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial. Arthritis research & therapy, 2015, Apr-06, Volume: 17 Topics: Adult; Aged; Arthritis, Rheumatoid; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Young Adult	2015
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Annals of the rheumatic diseases, 2016, Volume: 75, Issue:7 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2016
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis research & therapy, 2015, Nov-04, Volume: 17 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Self Report; Surveys and Questionnaires; Treatment Outcome	2015
Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis research & therapy, 2016, Jan-28, Volume: 18 Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Janus Kinase 3; Japan; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome	2016
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatology (Oxford, England), 2016, Volume: 55, Issue:6 Topics: Adalimumab; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Female; Humans; Male; Methotrexate; Middle Aged; Patient Reported Outcome Measures; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Severity of Illness Index; Treatment Outcome	2016
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitati Annals of the rheumatic diseases, 2016, Volume: 75, Issue:6 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Bone Marrow; Bone Marrow Diseases; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Edema; Female; Hand; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Synovitis; Treatment Outcome; Wrist Joint	2016
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis. Arthritis research & therapy, 2016, 06-23, Volume: 18 Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Substitution; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2016
Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial. Arthritis care & research, 2017, Volume: 69, Issue:4 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recovery of Function; Remission Induction; Time Factors; Treatment Outcome	2017
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group. Clinical rheumatology, 2017, Volume: 36, Issue:1 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinases; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Regression Analysis; Surveys and Questionnaires; Treatment Outcome	2017
[Comparative assessment of antiinflammatory action of atorvastatin in ischemic heart disease and rheumatoid arthritis]. Kardiologiia, 2008, Volume: 48, Issue:9 Topics: Arthritis, Rheumatoid; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Prospective Studies; Pyrroles; Treatment Outcome	2008
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis and rheumatism, 2009, Volume: 60, Issue:7 Topics: Arthritis, Rheumatoid; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Headache; Humans; International Cooperation; Janus Kinases; Male; Middle Aged; Nausea; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2009
Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Annals of the rheumatic diseases, 2010, Volume: 69, Issue:2 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Epidemiologic Methods; Female; Humans; Janus Kinase 3; Male; Middle Aged; Pain; Pain Measurement; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recovery of Function; Treatment Outcome	2010
[The use of atorvastatin in patients with rheumatoid arthritis with hyperlipidemia]. Kardiologiia, 2009, Volume: 49, Issue:9 Topics: Administration, Oral; Adult; Aged; Arthritis, Rheumatoid; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Treatment Outcome; Vascular Resistance	2009
A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis. Journal of clinical pharmacology, 2010, Volume: 50, Issue:6 Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Biological; Neutropenia; Piperidines; Pyrimidines; Pyrroles; Time Factors	2010
Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment. British journal of clinical pharmacology, 2010, Volume: 69, Issue:2 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2010
Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis. The Journal of rheumatology, 2011, Volume: 38, Issue:2 Topics: Adiponectin; Adult; Aged; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Drug Therapy, Combination; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Methotrexate; Middle Aged; Prednisone; Pyrroles; Regional Blood Flow; Resistin; Risk Factors; Severity of Illness Index; Tumor Necrosis Factor-alpha	2011
Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. Journal of lipid research, 2011, Volume: 52, Issue:5 Topics: Adult; Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Signal Transduction; T-Lymphocytes, Regulatory	2011
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis and rheumatism, 2012, Volume: 64, Issue:3 Topics: Adalimumab; Administration, Oral; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Substitution; Drug Tolerance; Female; Health Status; Humans; Injections, Subcutaneous; Janus Kinase 3; Joints; Male; Methotrexate; Middle Aged; Pilot Projects; Piperidines; Pyrimidines; Pyrroles; Recovery of Function	2012
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis and rheumatism, 2012, Volume: 64, Issue:4 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2012
In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Annals of the rheumatic diseases, 2012, Volume: 71 Suppl 2 Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; CD4-Positive T-Lymphocytes; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Isoenzymes; Janus Kinase 3; Mice; Mice, SCID; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction	2012
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. The New England journal of medicine, 2012, Aug-09, Volume: 367, Issue:6 Topics: Activities of Daily Living; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Janus Kinase 3; Least-Squares Analysis; Leukocyte Count; Male; Middle Aged; Neutrophils; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome	2012
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. The New England journal of medicine, 2012, Aug-09, Volume: 367, Issue:6 Topics: Adalimumab; Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Janus Kinase 3; Least-Squares Analysis; Leukocyte Count; Lipoproteins; Male; Methotrexate; Middle Aged; Neutrophils; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2012
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865 Topics: Adult; Aged; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Janus Kinases; Male; Maximum Tolerated Dose; Methotrexate; Middle Aged; Pain Measurement; Piperidines; Pyrimidines; Pyrroles; Recurrence; Risk Assessment; Severity of Illness Index; Time Factors; Treatment Failure; Treatment Outcome; Tumor Necrosis Factor-alpha	2013
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis and rheumatism, 2013, Volume: 65, Issue:3 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Resistance; Female; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Motor Activity; Piperidines; Pyrimidines; Pyrroles; Radiography; Treatment Outcome	2013
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (London, England), 2004, Jun-19, Volume: 363, Issue:9426 Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Biomarkers; Blood Sedimentation; Blood Viscosity; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Methotrexate; Middle Aged; Pyrroles; Risk Factors; von Willebrand Factor	2004
Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. The Journal of rheumatology, 2007, Volume: 34, Issue:7 Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Lipoproteins, HDL; Male; Middle Aged; Pilot Projects; Pyrroles	2007
Long-term efficacy and safety of tolmetin sodium in treatment of geriatric patients with rheumatoid arthritis and osteoarthritis: a retrospective study. Journal of clinical pharmacology, 1983, Volume: 23, Issue:7 Topics: Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Osteoarthritis; Pyrroles; Retrospective Studies; Time Factors; Tolmetin	1983
[Treatment of gonarthrosis with tolectin]. Therapeutische Umschau. Revue therapeutique, 1984, Volume: 41, Issue:5 Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Humans; Knee Joint; Male; Middle Aged; Pyrroles; Tolmetin	1984
Effectiveness of tolmetin in rheumatoid arthritis: evaluation by means of a new method. Methods and findings in experimental and clinical pharmacology, 1982, Volume: 4, Issue:3 Topics: Adult; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Pyrroles; Tolmetin	1982
Clinical experience with tolmetin sodium. Current medical research and opinion, 1980, Volume: 7, Issue:2 Topics: Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Double-Blind Method; Drug Tolerance; Fibromyalgia; Humans; Osteoarthritis; Phenylbutazone; Pyrroles; Tolmetin	1980
Tolmetin sodium, a new anti-arthritis drug: double-blind and long-term studies. Journal of the American Geriatrics Society, 1976, Volume: 24, Issue:10 Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Pressure; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Locomotion; Male; Middle Aged; Palliative Care; Placebos; Pyrroles; Time Factors; Tolmetin	1976
[Drug evaluation of McN-2559 in chronic rheumatoid arthritis]. Ryumachi. [Rheumatism], 1977, Volume: 17, Issue:1 Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Middle Aged; Pyrroles; Tolmetin	1977
[Evaluation of the therapeutic activity of a new nonsteroid antiphlogistic drug, Tolectin in rheumatoid arthritis]. Il Farmaco; edizione pratica, 1977, Volume: 31, Issue:7 Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Evaluation; Humans; Indomethacin; Pyrroles; Tolmetin	1977
Clinical trial of tolmetin and aspirin in the treatment of rheumatoid arthritis. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1977, Jul-23, Volume: 52, Issue:5 Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Pyrroles; Tolmetin	1977
Clinical studies with tolmetin: open study and a double-blind cross-over comparison with aspirin in rheumatoid arthritis. Rheumatology and rehabilitation, 1978, Volume: 17, Issue:3 Topics: Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Pyrroles; Tolmetin	1978
Comparative efficacy of pirprofen and aspirin in rheumatoid arthritis. Journal of clinical pharmacology, 1979, Volume: 19, Issue:1 Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Phenylpropionates; Pyrroles	1979
Pirprofen and aspirin in the treatment of rheumatoid arthritis. Clinical pharmacology and therapeutics, 1979, Volume: 25, Issue:5 Pt 1 Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Double-Blind Method; Eye Diseases; Female; Gastrointestinal Diseases; Hearing Disorders; Humans; Male; Middle Aged; Phenylpropionates; Pyrroles	1979
[1st data related to the study of a new drug. Tolmetin, in the treatment of rheumatoid arthritis. Preliminary communication]. La Clinica terapeutica, 1975, Oct-15, Volume: 75, Issue:1 Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Middle Aged; Pyrroles; Tolmetin	1975
Evaluation of tolmetin in the treatment of arthritis: open and controlled double-blind studies. Current medical research and opinion, 1976, Volume: 4, Issue:2 Topics: Adult; Arthritis, Rheumatoid; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Indomethacin; Male; Middle Aged; Pyrroles; Tolmetin	1976
A double-blind cross-over study of clopirac and ketoprofen in rheumatoid arthritis. Journal belge de rhumatologie et de medecine physique = Belgisch tijdschrift voor reumatologie en fysische geneeskunde, 1975, Volume: 30 Spec no Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Benzophenones; Clinical Trials as Topic; Humans; Ketoprofen; Pyrroles	1975
[Clinical study with 1-parachlorophenyl-2,5-dimethyl-3-pyrrolacetic acid "clopirac" (author's transl)]. Journal belge de rhumatologie et de medecine physique = Belgisch tijdschrift voor reumatologie en fysische geneeskunde, 1975, Volume: 30 Spec no Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Indomethacin; Pyrroles	1975
A double-blind comparison of clopirac and indomethacin in the treatment of rheumatoid arthritis. Journal belge de rhumatologie et de medecine physique = Belgisch tijdschrift voor reumatologie en fysische geneeskunde, 1975, Volume: 30 Spec no Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Indomethacin; Pyrroles	1975
[Double-blind study of clopirac and indomethacin in rheumatoid arthritis (author's transl)]. Journal belge de rhumatologie et de medecine physique = Belgisch tijdschrift voor reumatologie en fysische geneeskunde, 1975, Volume: 30 Spec no Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Humans; Indomethacin; Male; Middle Aged; Pyrroles	1975
Treatment of rheumatoid arthritis with clopirac: comparison with aspirin. Journal belge de rhumatologie et de medecine physique = Belgisch tijdschrift voor reumatologie en fysische geneeskunde, 1975, Volume: 30 Spec no Topics: Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Humans; Pyrroles	1975
Double-blind study comparing clopirac with a placebo in rheumatoid arthritis. Journal belge de rhumatologie et de medecine physique = Belgisch tijdschrift voor reumatologie en fysische geneeskunde, 1975, Volume: 30 Spec no Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Placebos; Pyrroles	1975
[Study of a new anti-inflammatory agent in rheumatoid arthritis (author's transl)]. Journal belge de rhumatologie et de medecine physique = Belgisch tijdschrift voor reumatologie en fysische geneeskunde, 1975, Volume: 30 Spec no Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Indomethacin; Pyrroles	1975
[Double-blind cross-over clinical study comparing clopirac with indomethacin in rheumatoid arthritis (author's transl)]. Journal belge de rhumatologie et de medecine physique = Belgisch tijdschrift voor reumatologie en fysische geneeskunde, 1975, Volume: 30 Spec no Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Indomethacin; Pyrroles	1975
European experiences with tolmetin in the treatment of rheumatic diseases. Current therapeutic research, clinical and experimental, 1976, Volume: 19, Issue:3 Topics: Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Humans; Indomethacin; Male; Middle Aged; Osteoarthritis; Oxyphenbutazone; Placebos; Pyrroles; Rheumatic Diseases; Tolmetin; Wounds and Injuries	1976
Tolmetin: an evaluation of a new preparation in the treatment of rheumatoid arthritis. The British journal of clinical practice, 1975, Volume: 29, Issue:8 Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Middle Aged; Pyrroles; Tolmetin	1975
[Double blind and dosage studies on tolectine in rheumatoid arthritis]. Zeitschrift fur Allgemeinmedizin, 1975, Oct-31, Volume: 51, Issue:30 Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Male; Middle Aged; Placebos; Pyrroles; Tolmetin	1975
A dual approach to the evaluation of the efficacy of a new rheumatoid arthritic agent--pirprofen. Journal of clinical pharmacology, 1976, Volume: 16, Issue:1 Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Blood Pressure; Clinical Trials as Topic; Female; Heart Rate; Humans; Male; Middle Aged; Phenylpropionates; Placebos; Pyrroles	1976
Double-blind cross-over study of clopirac and naproxen in rheumatoid arthritis. Journal belge de rhumatologie et de medecine physique = Belgisch tijdschrift voor reumatologie en fysische geneeskunde, 1975, Volume: 30 Spec no Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Humans; Naphthaleneacetic Acids; Naproxen; Pyrroles	1975
[Study in double-blind comparing clopirac to indomethacine in rheumatoid arthritis (author's transl)]. Journal belge de rhumatologie et de medecine physique = Belgisch tijdschrift voor reumatologie en fysische geneeskunde, 1975, Volume: 30 Spec no Topics: Arthritis, Rheumatoid; Humans; Indomethacin; Pyrroles	1975
A clinical and biochemical assessment of prinomide in patients with rheumatoid arthritis. The Journal of rheumatology, 1989, Volume: 16, Issue:4 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Pyrroles; Statistics as Topic	1989
Tolmetin versus placebo for the treatment of rheumatoid arthritis: a sequential double-blind clinical trial. Current therapeutic research, clinical and experimental, 1974, Volume: 16, Issue:5 Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Benzoates; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Placebos; Pyrroles	1974
Tolerance to pirprofen and preliminary efficacy trial in rheumatoid arthritis. Clinical pharmacology and therapeutics, 1974, Volume: 16, Issue:1 Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Indomethacin; Joints; Male; Middle Aged; Phenylpropionates; Placebos; Prisoners; Pyrroles; Time Factors	1974
Tolectin for rheumatoid arthritis. Rheumatology and rehabilitation, 1974, Volume: 13, Issue:3 Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Benzoates; Clinical Trials as Topic; Humans; Phenylbutazone; Placebos; Pyrroles	1974

Other Studies

218 other study(ies) available for pyrroles and Arthritis, Rheumatoid

Article	Year
Systemic inflammatory responses after orthopedic surgery in patients with rheumatoid arthritis treated with tofacitinib. Clinical rheumatology, 2021, Volume: 40, Issue:12 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Infant, Newborn; Orthopedic Procedures; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Treatment Outcome	2021
Tofacitinib for the treatment of rheumatoid arthritis: a real-world study in China. Internal and emergency medicine, 2022, Volume: 17, Issue:3 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; China; Humans; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Treatment Outcome	2022
Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis. Advances in therapy, 2021, Volume: 38, Issue:12 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome	2021
Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2022, Jan-01, Volume: 1188 Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Chromatography, Liquid; Drug Monitoring; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Limit of Detection; Linear Models; Pyrroles; Reproducibility of Results; Tandem Mass Spectrometry	2022
Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data. Rheumatology (Oxford, England), 2022, 10-06, Volume: 61, Issue:10 Topics: Abatacept; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Biological Products; Cohort Studies; Humans; Interleukin-6; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Rituximab; Sulfonamides; Sweden; Treatment Outcome; Tumor Necrosis Factor Inhibitors	2022
Work productivity in rheumatoid arthritis patients from two Latin American countries treated with tofacitinib or biological DMARDs. Expert review of pharmacoeconomics & outcomes research, 2022, Volume: 22, Issue:5 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Efficiency; Humans; Latin America; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Work Performance	2022
Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTOR App. International journal of environmental research and public health, 2022, 04-28, Volume: 19, Issue:9 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Mobile Applications; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2022
Real-world evidence of the effectiveness and safety of generic tofacitinib in rheumatoid arthritis patients: a retrospective, single-centre analysis from Western India. Clinical rheumatology, 2022, Volume: 41, Issue:10 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; COVID-19; Female; Humans; India; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Treatment Outcome	2022
Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational Study. Arthritis care & research, 2023, Volume: 75, Issue:2 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Humans; Prospective Studies; Pyrroles; Treatment Outcome	2023
[What do the results of the ORAL surveillance study mean for the treatment of rheumatoid arthritis with tofacitinib?] Nederlands tijdschrift voor geneeskunde, 2022, 06-09, Volume: 166 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reproducibility of Results; Treatment Outcome	2022
Tofacitinib as a possible treatment for arthritis in an APDS2 patient. Rheumatology (Oxford, England), 2023, 03-01, Volume: 62, Issue:3 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2023
Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry. Clinical and experimental rheumatology, 2023, Volume: 41, Issue:5 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Pyrroles; Republic of Korea; Rheumatology; Treatment Outcome	2023
Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response. Clinical and experimental immunology, 2022, 12-15, Volume: 210, Issue:2 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Blood Proteins; Chemokines; Humans; Inflammation; Interleukin-6; Protein Kinase Inhibitors; Pyrroles; Treatment Outcome	2022
Real-world Effectiveness and Safety of JAK Inhibitors in Rheumatoid Arthritis: A Single-centre Study. Reumatologia clinica, 2022, Volume: 18, Issue:9 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Humans; Janus Kinase Inhibitors; Pyrroles; Retrospective Studies	2022
Safety and effectiveness of tofacitinib in Korean adult patients with rheumatoid arthritis: A post-marketing surveillance study. Modern rheumatology, 2023, Nov-01, Volume: 33, Issue:6 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Product Surveillance, Postmarketing; Prospective Studies; Pyrroles; Republic of Korea; Treatment Outcome	2023
Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy. Reumatismo, 2022, Dec-29, Volume: 74, Issue:3 Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome	2022
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme. Annals of the rheumatic diseases, 2023, Volume: 82, Issue:4 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Incidence; Pyrroles; Risk Factors; Treatment Outcome	2023
Letter: tofacitinib in the real world - do clinical trial data stand up? Alimentary pharmacology & therapeutics, 2023, Volume: 57, Issue:6 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Piperidines; Pyrimidines; Pyrroles	2023
Development of a sensitive biochemical assay for the detection of tofacitinib adherence. Analytical methods : advancing methods and applications, 2023, 04-06, Volume: 15, Issue:14 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Pyrroles; Tandem Mass Spectrometry	2023
Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab. Arthritis research & therapy, 2023, 04-27, Volume: 25, Issue:1 Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Humans; Patient Satisfaction; Personal Satisfaction; Pyrroles; Quality of Life; Treatment Outcome	2023
Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start. Arthritis research & therapy, 2023, 09-29, Volume: 25, Issue:1 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Pyrroles; Treatment Outcome	2023
Outcomes of dose reduction, withdrawal, and restart of tofacitinib in patients with rheumatoid arthritis: a prospective observational study. Clinical rheumatology, 2019, Volume: 38, Issue:12 Topics: Aged; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Symptom Flare Up	2019
Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years. Rheumatology (Oxford, England), 2020, 03-01, Volume: 59, Issue:3 Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Databases, Factual; Female; Humans; Male; Middle Aged; Piperidines; Practice Patterns, Physicians'; Pyrimidines; Pyrroles; Treatment Outcome	2020
Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo International journal of rheumatic diseases, 2019, Volume: 22, Issue:12 Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Drug Administration Schedule; Fluorodeoxyglucose F18; Janus Kinase Inhibitors; Joints; Male; Mice, Inbred DBA; Piperidines; Positron-Emission Tomography; Predictive Value of Tests; Pyrimidines; Pyrroles; Radiopharmaceuticals; Whole Body Imaging	2019
Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis. Mediators of inflammation, 2019, Volume: 2019 Topics: Adult; Arthritis, Rheumatoid; Cytokines; Female; Humans; Interleukin-17; Interleukin-6; Interleukins; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha	2019
IgA Vasculitis Developed as an Adverse Effect of Tofacitinib Taken for Rheumatoid Arthritis. Internal medicine (Tokyo, Japan), 2020, Mar-15, Volume: 59, Issue:6 Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Immunoglobulin A; Piperidines; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha; Vasculitis	2020
Alterations of voluntary behavior in the course of disease progress and pharmacotherapy in mice with collagen-induced arthritis. Arthritis research & therapy, 2019, 12-12, Volume: 21, Issue:1 Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Disease Models, Animal; Disease Progression; Humans; Joints; Male; Mice, Inbred DBA; Motor Activity; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Synovitis; Temperature	2019
Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacology research & perspectives, 2019, Volume: 7, Issue:6 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Cell Line; Cytokines; Enzyme Assays; Female; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; Humans; Inhibitory Concentration 50; Janus Kinase 1; Janus Kinase Inhibitors; Male; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptors, Cytokine; Sulfonamides; Triazoles	2019
Inferring disease severity in rheumatoid arthritis using predictive modeling in administrative claims databases. PloS one, 2019, Volume: 14, Issue:12 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Female; Humans; Insurance Claim Review; Male; Middle Aged; Models, Biological; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index	2019
Methotrexate-Induced Pneumonitis in Rheumatoid Arthritis: Long-term Treatment With Tofacitinib Therapy. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2021, Dec-01, Volume: 27, Issue:8S Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pneumonia; Pyrimidines; Pyrroles; Treatment Outcome	2021
Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis. Zeitschrift fur Rheumatologie, 2020, Volume: 79, Issue:8 Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles	2020
Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib. Annals of the rheumatic diseases, 2020, Volume: 79, Issue:5 Topics: Aged; Arthritis, Rheumatoid; Combined Modality Therapy; Female; Follow-Up Studies; Herpes Zoster Vaccine; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome; Vaccines, Live, Unattenuated	2020
The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Journal of the American Academy of Dermatology, 2020, Volume: 82, Issue:6 Topics: Arthritis, Rheumatoid; Azetidines; Betacoronavirus; Colitis, Ulcerative; Coronavirus Infections; COVID-19; Cytokines; Dermatitis, Atopic; Heterocyclic Compounds, 3-Ring; Humans; Immunomodulation; Janus Kinases; Nitriles; Pandemics; Piperidines; Pneumonia, Viral; Primary Myelofibrosis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; SARS-CoV-2; STAT Transcription Factors; Sulfonamides	2020
Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain. Clinical rheumatology, 2020, Volume: 39, Issue:10 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Spain; Treatment Outcome	2020
Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTORApp-A Usability Study. International journal of environmental research and public health, 2020, 05-15, Volume: 17, Issue:10 Topics: Adolescent; Adult; Arthritis, Rheumatoid; Computer Security; Female; Humans; Medication Adherence; Mobile Applications; Piperidines; Pregnancy; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Young Adult	2020
Tofacitinib-induced Ramsay- Hunt Syndrome in a Patient with Rheumatoid Arthritis. Current drug safety, 2021, Volume: 16, Issue:1 Topics: Arthritis, Rheumatoid; Female; Herpes Zoster Oticus; Humans; Middle Aged; Piperidines; Pyrimidines; Pyrroles	2021
Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analysis From 21 Clinical Trials. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2021, Dec-01, Volume: 27, Issue:8 Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Incidence; Lung Diseases, Interstitial; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2021
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management. Inflammatory bowel diseases, 2021, 05-17, Volume: 27, Issue:6 Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cholesterol; Clinical Trials, Phase III as Topic; Colitis, Ulcerative; Heart Disease Risk Factors; Humans; Inflammation; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Risk Factors; Treatment Outcome	2021
Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates? Annals of the rheumatic diseases, 2020, Volume: 79, Issue:11 Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Humans; Incidence; Piperidines; Psoriasis; Pulmonary Embolism; Pyrimidines; Pyrroles	2020
Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan. Medicine, 2020, Oct-09, Volume: 99, Issue:41 Topics: Aged; Arthritis, Rheumatoid; Case-Control Studies; Female; Herpes Zoster; Humans; Incidence; Interferon-gamma; Lymphocyte Count; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocytes; Taiwan	2020
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis. Advances in therapy, 2021, Volume: 38, Issue:1 Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Medicare; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome; United States	2021
Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor: A case report. Medicine, 2020, Oct-16, Volume: 99, Issue:42 Topics: Aged; Arthritis, Rheumatoid; Castleman Disease; Fatal Outcome; Female; Humans; Janus Kinase Inhibitors; Multiple Organ Failure; Piperidines; Pyrimidines; Pyrroles; Thrombocytopenia	2020
Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study. Clinical rheumatology, 2021, Volume: 40, Issue:7 Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Cohort Studies; Female; Humans; Methotrexate; Middle Aged; Pharmaceutical Preparations; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome	2021
Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2021, Volume: 32, Issue:8 Topics: Arthritis, Rheumatoid; Bone Density; Humans; Piperidines; Pyrimidines; Pyrroles	2021
Development and evaluation of tofacitinib transdermal system for the treatment of rheumatoid arthritis in rats. Drug development and industrial pharmacy, 2021, Volume: 47, Issue:6 Topics: Administration, Cutaneous; Animals; Arthritis, Rheumatoid; Drug Delivery Systems; Piperidines; Pyrimidines; Pyrroles; Rats; Transdermal Patch	2021
Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis. Arthritis research & therapy, 2021, 07-23, Volume: 23, Issue:1 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Humans; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome	2021
Adherence to treatment with tofacitinib in patients with rheumatoid arthritis in daily clinical practice. Reumatologia clinica, 2022, Volume: 18, Issue:3 Topics: Adolescent; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles	2022
Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production. Clinical and experimental immunology, 2017, Volume: 189, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Azetidines; Case-Control Studies; Cell Movement; Cells, Cultured; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-8; Janus Kinases; Male; Middle Aged; Neutrophils; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Reactive Oxygen Species; Respiratory Burst; Sulfonamides; Tetradecanoylphorbol Acetate; United Kingdom	2017
Cytomegalovirus retinitis followed by immune recovery uveitis in an elderly patient with rheumatoid arthritis undergoing administration of methotrexate and tofacitinib combination therapy. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2017, Volume: 23, Issue:8 Topics: Aged; Antiviral Agents; Arthritis, Rheumatoid; Cytomegalovirus Retinitis; Ganciclovir; Humans; Immunosuppressive Agents; Intravitreal Injections; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Uveitis	2017
Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study. Rheumatology (Oxford, England), 2017, 08-01, Volume: 56, Issue:8 Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Humans; Male; Middle Aged; Piperidines; Prospective Studies; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome; Withholding Treatment	2017
Tofacitinib attenuates arthritis manifestations and reduces the pathogenic CD4 T cells in adjuvant arthritis rats. Clinical immunology (Orlando, Fla.), 2017, Volume: 184 Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; C-Reactive Protein; CD4-Positive T-Lymphocytes; Foot; Foot Joints; Forelimb; Hindlimb; Interferon-gamma; Interleukin-1beta; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spleen	2017
Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. PloS one, 2017, Volume: 12, Issue:5 Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles	2017
Jak3 deficiency blocks innate lymphoid cell development. Mucosal immunology, 2018, Volume: 11, Issue:1 Topics: Animals; Arthritis, Rheumatoid; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Cells, Cultured; Humans; Immunity, Innate; Interferon-gamma; Janus Kinase 3; Killer Cells, Natural; Mice; Mice, Mutant Strains; Mutation; Phenotype; Piperidines; Pyrimidines; Pyrroles; Severe Combined Immunodeficiency	2018
Electronically Activated Organoboron Catalysts for Enantioselective Propargyl Addition to Trifluoromethyl Ketones. Angewandte Chemie (International ed. in English), 2017, 07-17, Volume: 56, Issue:30 Topics: Arthritis, Rheumatoid; Benzamides; Boron Compounds; Catalysis; Electronics; Ketones; Molecular Structure; Morphinans; Pyridines; Pyrroles; Stereoisomerism	2017
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:8 Topics: Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Biological Products; Glucocorticoids; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Orthopedics; Perioperative Care; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rheumatic Diseases; Rheumatology; Societies, Medical; Spondylitis, Ankylosing; United States	2017
Treating active rheumatoid arthritis with Janus kinase inhibitors. Lancet (London, England), 2017, 07-29, Volume: 390, Issue:10093 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinase Inhibitors; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrroles	2017
Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis. British journal of pharmacology, 2017, Volume: 174, Issue:18 Topics: Animals; Arthritis, Rheumatoid; Cholesterol; Diet, High-Fat; Dose-Response Relationship, Drug; Inflammation; Lipids; Macrophages; Male; Piperidines; Pyrimidines; Pyrroles; Rabbits; Structure-Activity Relationship	2017
Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Annals of the rheumatic diseases, 2018, Volume: 77, Issue:5 Topics: Adult; Arthritis, Rheumatoid; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Taiwan; Virus Activation	2018
Rheumatoid arthritis: JAK-ing up inadequate RA therapy. Nature reviews. Rheumatology, 2017, Volume: 13, Issue:9 Topics: Adalimumab; Arthritis, Rheumatoid; Double-Blind Method; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles	2017
Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis. Autoimmunity, 2017, Volume: 50, Issue:5 Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Line; Cell Proliferation; Female; Humans; Insulin-Like Growth Factor I; Macrophage Colony-Stimulating Factor; Mice; Neovascularization, Pathologic; Osteoclasts; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; RANK Ligand; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction	2017
A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis. Scientific reports, 2017, 07-28, Volume: 7, Issue:1 Topics: Administration, Oral; Adult; Animals; Arthritis, Rheumatoid; Candida albicans; Candidiasis; Disease Susceptibility; Female; Humans; Mice, Inbred BALB C; Neutrophil Activation; Neutrophils; Phagocytosis; Piperidines; Pyrimidines; Pyrroles; Risk Factors	2017
Novel drug delivery of dual acting prodrugs of hydroxychloroquine with aryl acetic acid NSAIDs: Design, kinetics and pharmacological study. Drug delivery and translational research, 2017, Volume: 7, Issue:5 Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Arthritis, Rheumatoid; Carrageenan; Diclofenac; Drug Design; Female; Freund's Adjuvant; Hydroxychloroquine; Inflammation; Male; Mice; Prodrugs; Pyrroles; Rats; Rats, Wistar	2017
Editorial: Herpes Zoster: Fear the Infection, Value the Solution. Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:10 Topics: Arthritis, Rheumatoid; Fear; Herpes Zoster; Humans; Piperidines; Pyrimidines; Pyrroles; Vaccination	2017
Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:10 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Clinical Trials as Topic; Databases, Factual; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucocorticoids; Herpes Zoster; Humans; Incidence; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Multivariate Analysis; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors	2017
Rheumatoid arthritis: Reducing the risk of herpes zoster. Nature reviews. Rheumatology, 2017, Volume: 13, Issue:11 Topics: Arthritis, Rheumatoid; Herpes Zoster; Humans; Piperidines; Pyrimidines; Pyrroles; Vaccination	2017
Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program. Arthritis care & research, 2018, Volume: 70, Issue:5 Topics: Adult; Aged; Arthritis, Rheumatoid; Case-Control Studies; Female; Humans; Janus Kinase 3; Lymphoma; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles	2018
Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis. Archiv der Pharmazie, 2017, Volume: 350, Issue:11 Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Disease Progression; Female; Humans; Inhibitory Concentration 50; Janus Kinase 3; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley	2017
Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study. Rheumatology international, 2017, Volume: 37, Issue:12 Topics: Adult; Aged; Arthritis, Rheumatoid; Atherosclerosis; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol; Cohort Studies; Drug Administration Schedule; Female; Humans; Intention to Treat Analysis; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors; Single-Blind Method; Surveys and Questionnaires; Ultrasonography; Up-Regulation	2017
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA. Advances in therapy, 2017, Volume: 34, Issue:11 Topics: Abatacept; Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Databases, Factual; Etanercept; Female; Humans; Infliximab; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Tumor Necrosis Factor-alpha	2017
NICE issues positive recommendation for XELJANZ®▼(tofacitinib citrate) as a new treatment option for adults with severe rheumatoid arthritis. Rheumatology (Oxford, England), 2017, Dec-01, Volume: 56, Issue:12 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Approval; Humans; Piperidines; Pyrimidines; Pyrroles; United Kingdom	2017
Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation. Rheumatology international, 2018, Volume: 38, Issue:4 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Disease Progression; Drug Therapy, Combination; Ethics, Research; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recurrence; Remission Induction; Research Design; Research Subjects; Time Factors; Treatment Outcome; Vulnerable Populations	2018
A Case Series on Patients on Tofacitinib in Combination With a Biologic. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2018, Volume: 24, Issue:6 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Janus Kinase 3; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome	2018
Bone remodelling: locus minori or unappreciated potential of tofacitinib? Rheumatology (Oxford, England), 2018, 08-01, Volume: 57, Issue:8 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bone Remodeling; Double-Blind Method; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2018
Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib. Pharmacology research & perspectives, 2018, Volume: 6, Issue:1 Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Clinical Trials as Topic; Feasibility Studies; Female; Humans; Incidence; Janus Kinase Inhibitors; Japan; Male; Middle Aged; Pancreatic Neoplasms; Pharmacovigilance; Piperidines; Product Surveillance, Postmarketing; Pyrimidines; Pyrroles	2018
Tofacitinib for Psoriatic Arthritis. The New England journal of medicine, 2018, 02-22, Volume: 378, Issue:8 Topics: Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2018
Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib. Dermatology online journal, 2018, Jan-15, Volume: 24, Issue:1 Topics: Arthritis, Rheumatoid; Chronic Disease; Female; Herpes Zoster; Humans; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin; Skin Ulcer	2018
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. Arthritis research & therapy, 2018, 03-23, Volume: 20, Issue:1 Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Infections; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Treatment Outcome	2018
Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways. International immunopharmacology, 2018, Volume: 58 Topics: Animals; Arthritis, Rheumatoid; Bone Resorption; Cyclic S-Oxides; Gene Expression Regulation; Genes, fos; Humans; Janus Kinases; Macrophages; Mice; NF-kappa B; NFATC Transcription Factors; Osteogenesis; Piperidines; Pyrimidines; Pyrroles; RANK Ligand; RAW 264.7 Cells; Signal Transduction; STAT3 Transcription Factor	2018
Elderly-Onset Varicella Pneumonia in a Patient With Rheumatoid Arthritis Treated With Tofacitinib. Arthritis & rheumatology (Hoboken, N.J.), 2018, Volume: 70, Issue:8 Topics: Aged; Arthritis, Rheumatoid; Chickenpox; Female; Herpesvirus 3, Human; Humans; Piperidines; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrimidines; Pyrroles	2018
Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients. Arthritis research & therapy, 2018, 05-02, Volume: 20, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Logistic Models; Male; Methotrexate; Middle Aged; Patient Compliance; Physicians; Piperidines; Prescriptions; Pyrimidines; Pyrroles; Risk Factors	2018
JAK/STAT Blockade Alters Synovial Bioenergetics, Mitochondrial Function, and Proinflammatory Mediators in Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.), 2018, Volume: 70, Issue:12 Topics: Arthritis, Rheumatoid; Cells, Cultured; Energy Metabolism; Fibroblasts; Humans; Inflammation Mediators; Janus Kinases; Mitochondria; Oncostatin M; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors; Synovial Membrane	2018
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate. Journal of translational medicine, 2018, 06-07, Volume: 16, Issue:1 Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Inflammation; Methotrexate; Phenotype; Piperidines; Pyrimidines; Pyrroles; Receptors, Interleukin-6; Signal Transduction	2018
An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective. Journal of managed care & specialty pharmacy, 2018, Volume: 24, Issue:10 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Clinical Decision-Making; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Drug Costs; Drug Substitution; Humans; Methotrexate; Models, Economic; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Remission Induction; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; United States	2018
Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis. Molecular pharmaceutics, 2018, 08-06, Volume: 15, Issue:8 Topics: Acrylamides; Administration, Oral; Animals; Ankle Joint; Arthritis, Experimental; Arthritis, Rheumatoid; Cells, Cultured; Janus Kinase Inhibitors; Janus Kinases; Macrophages; Male; Mice, Inbred C57BL; Piperidines; Primary Cell Culture; Prodrugs; Pyrimidines; Pyrroles; Rats; Rats, Inbred Lew; Signal Transduction; STAT6 Transcription Factor; Tissue Distribution; Treatment Outcome; X-Ray Microtomography	2018
Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States. Current medical research and opinion, 2018, Volume: 34, Issue:11 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost Savings; Cost-Benefit Analysis; Humans; Models, Economic; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Treatment Outcome; United States	2018
Tofacitinib and Risk of Peripheral Neuropathy? Experience of 2 Cases in Patients With Rheumatoid Arthritis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2021, Mar-01, Volume: 27, Issue:2 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Peripheral Nervous System Diseases; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2021
Comments on the article "Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study". Arthritis research & therapy, 2018, 08-29, Volume: 20, Issue:1 Topics: Arthritis, Rheumatoid; Cohort Studies; Humans; Piperidines; Pyrimidines; Pyrroles	2018
Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism. The journal of medical investigation : JMI, 2018, Volume: 65, Issue:3.4 Topics: Adiposity; Adult; Aged; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Body Composition; Diet, High-Fat; Female; Glucose; Humans; Janus Kinase Inhibitors; Lipolysis; Mice; Mice, Inbred C57BL; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Weight Gain	2018
Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids. Arthritis care & research, 2019, Volume: 71, Issue:9 Topics: Aged; Arthritis, Rheumatoid; Databases, Factual; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Herpes Zoster; Humans; Incidence; Janus Kinase Inhibitors; Male; Medicare; Methotrexate; Middle Aged; Multivariate Analysis; Piperidines; Pyrimidines; Pyrroles; Risk Assessment; Time Factors; United States	2019
An Immune Suppression-associated EBV-positive Anaplastic Large Cell Lymphoma With a BRAF V600E Mutation. The American journal of surgical pathology, 2019, Volume: 43, Issue:1 Topics: Aged; Arthritis, Rheumatoid; Epstein-Barr Virus Infections; Humans; Immunocompromised Host; Lymphoma, Large-Cell, Anaplastic; Male; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines; Pyrroles	2019
Dr. Charles-Schoeman and E. Bananis Reply. The Journal of rheumatology, 2018, Volume: 45, Issue:11 Topics: Arthritis, Rheumatoid; Glucocorticoids; Humans; Piperidines; Pyrimidines; Pyrroles	2018
Effects of Co-medication with Glucocorticoids in Biologics Trials. The Journal of rheumatology, 2018, Volume: 45, Issue:11 Topics: Arthritis, Rheumatoid; Biological Products; Glucocorticoids; Humans; Piperidines; Pyrimidines; Pyrroles	2018
Decrease in 14-3-3η protein levels is correlated with improvement in disease activity in patients with rheumatoid arthritis treated with Tofacitinib. Pharmacological research, 2019, Volume: 141 Topics: 14-3-3 Proteins; Adult; Arthritis, Rheumatoid; Biomarkers; Cohort Studies; Female; Humans; Male; Middle Aged; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles	2019
Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:5 Topics: Arthritis, Rheumatoid; B-Lymphocytes; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Humans; Incidence; Infections; Janus Kinase Inhibitors; Killer Cells, Natural; Lymphocyte Count; Piperidines; Pyrimidines; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes; Time Factors	2019
HDAC10 upregulation contributes to interleukin 1β-mediated inflammatory activation of synovium-derived mesenchymal stem cells in temporomandibular joint. Journal of cellular physiology, 2019, Volume: 234, Issue:8 Topics: Arthritis, Rheumatoid; Cells, Cultured; Fibroblasts; Histone Deacetylases; Humans; Hydroxamic Acids; Interleukin-1beta; Interleukin-8; Mesenchymal Stem Cells; NF-kappa B; Osteoarthritis; Pyrroles; Signal Transduction; Synovial Membrane; Synoviocytes; Temporomandibular Joint; Transcriptional Activation; Up-Regulation	2019
Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:6 Topics: Adult; Aged; Arthritis, Rheumatoid; Cohort Studies; Databases, Factual; Female; Humans; Incidence; Janus Kinase Inhibitors; Male; Middle Aged; Piperidines; Proportional Hazards Models; Pulmonary Embolism; Pyrimidines; Pyrroles; Tumor Necrosis Factor Inhibitors; Venous Thromboembolism; Venous Thrombosis	2019
Comparisons of hepatitis C viral replication in patients with rheumatoid arthritis receiving tocilizumab, abatacept and tofacitinib therapy. Annals of the rheumatic diseases, 2019, Volume: 78, Issue:6 Topics: Abatacept; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Piperidines; Prospective Studies; Pyrimidines; Pyrroles; Virus Replication	2019
2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis. Advances in rheumatology (London, England), 2018, May-24, Volume: 58, Issue:1 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Brazil; Decision Making; Drug Substitution; Drug Therapy, Combination; Glucocorticoids; Humans; Hydroxychloroquine; Leflunomide; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Rheumatology; Societies, Medical; Sulfasalazine	2018
Reversible eruption of neurofibromatosis associated with tofacitinib therapy for rheumatoid arthritis. Rheumatology (Oxford, England), 2019, 06-01, Volume: 58, Issue:6 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Fibroma; Humans; Middle Aged; Neurofibromatosis 1; Piperidines; Pyrimidines; Pyrroles; Skin Neoplasms	2019
Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis. European journal of medicinal chemistry, 2019, May-01, Volume: 169 Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Collagen; Dose-Response Relationship, Drug; Drug Design; Humans; Male; Mice; Mice, Inbred DBA; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship	2019
Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data. International journal of rheumatic diseases, 2019, Volume: 22, Issue:6 Topics: Adult; Arthritis, Rheumatoid; Asia; Clinical Trials as Topic; Evidence-Based Medicine; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Neoplasms; Opportunistic Infections; Piperidines; Pyrimidines; Pyrroles; Recovery of Function; Remission Induction; Risk Factors; Time Factors; Treatment Outcome	2019
Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib. Frontiers in immunology, 2019, Volume: 10 Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Cell Proliferation; Chemokine CCL2; Fibroblasts; Humans; Interleukin-6; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Synovial Membrane	2019
Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs. Advances in therapy, 2019, Volume: 36, Issue:6 Topics: Adalimumab; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Certolizumab Pegol; Cost-Benefit Analysis; Etanercept; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Young Adult	2019
Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib. Rheumatology international, 2019, Volume: 39, Issue:7 Topics: Adiposity; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; Female; Humans; Intra-Abdominal Fat; Male; Middle Aged; Obesity, Abdominal; Piperidines; Prospective Studies; Pyrimidines; Pyrroles; Waist Circumference	2019
Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis. Rheumatology (Oxford, England), 2019, 11-01, Volume: 58, Issue:11 Topics: Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Arthritis, Rheumatoid; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Proliferation; Herpesvirus 3, Human; Humans; Immunity, Cellular; Interferon-gamma; Lectins, C-Type; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, CCR5; Receptors, CXCR3; Th1 Cells	2019
Chronic Inguinal Lymphadenitis in a Patient With Rheumatoid Arthritis Being Treated With Tofacitinib: Remission With Antituberculous Therapy and Discontinuation of JAK Inhibition. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2020, Volume: 26, Issue:5 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Lymphadenitis; Piperidines; Pyrimidines; Pyrroles	2020
Budget impact of introducing tofacitinib to the public hospital formulary in Hong Kong, 2017-2021. Hong Kong medical journal = Xianggang yi xue za zhi, 2019, Volume: 25, Issue:3 Topics: Arthritis, Rheumatoid; Biological Products; Health Care Costs; Hong Kong; Hospitals, Public; Humans; Linear Models; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles	2019
Tofacitinib: raising awareness of mycoses. Internal medicine journal, 2019, Volume: 49, Issue:6 Topics: Aged; Arthritis, Rheumatoid; Fingers; Humans; Male; Mycoses; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles	2019
IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes : JAKinibs suppress the interferon response in RA-FLSs. Experimental & molecular medicine, 2019, 07-08, Volume: 51, Issue:7 Topics: Animals; Arthritis, Rheumatoid; Azetidines; Biomarkers; Female; Gene Expression; Humans; Inflammation; Interferon Regulatory Factor-1; Interferons; Janus Kinase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Transgenic; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Sulfonamides; Synovial Membrane; Synoviocytes; Tumor Necrosis Factor-alpha	2019
Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats. The AAPS journal, 2019, 07-24, Volume: 21, Issue:5 Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Edema; Male; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Inbred Lew	2019
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis research & therapy, 2019, 08-02, Volume: 21, Issue:1 Topics: Arthritis, Rheumatoid; Azetidines; Biomarkers; Cytokines; Flow Cytometry; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Leukocytes, Mononuclear; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Sulfonamides	2019
Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases. Advances in therapy, 2019, Volume: 36, Issue:9 Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Biological Products; Female; Humans; Inflammatory Bowel Diseases; Infliximab; Insurance Claim Review; Male; Medication Adherence; Medication Therapy Management; Middle Aged; Piperidines; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; United States	2019
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:9 Topics: Aged; Arthritis, Rheumatoid; Blood Sedimentation; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors; Stroke; Treatment Outcome	2019
Update in rheumatology: evidence published in 2012. Annals of internal medicine, 2013, Jun-18, Volume: 158, Issue:12 Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Antiviral Agents; Arthritis; Arthritis, Gouty; Arthritis, Rheumatoid; Autoimmune Diseases; Bacterial Infections; Calcitonin; Colchicine; Cryoglobulinemia; Death, Sudden, Cardiac; Drug Resistance, Viral; Enzyme Inhibitors; Female; Gout; Gout Suppressants; Hand Joints; Hepatitis C, Chronic; Humans; Hyperuricemia; Immunologic Factors; Janus Kinase 3; Male; Myocardial Infarction; Neoplasms; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Practice Guidelines as Topic; Protein Precursors; Pyrimidines; Pyrroles; Registries; Tumor Necrosis Factor-alpha	2013
Tofacitinib for rheumatoid arthritis. Lancet (London, England), 2013, May-25, Volume: 381, Issue:9880 Topics: Arthritis, Rheumatoid; Female; Humans; Janus Kinases; Male; Methotrexate; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha	2013
Tofacitinib for rheumatoid arthritis - Authors' reply. Lancet (London, England), 2013, May-25, Volume: 381, Issue:9880 Topics: Arthritis, Rheumatoid; Female; Humans; Janus Kinases; Male; Methotrexate; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha	2013
Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds. Clinical and experimental immunology, 2013, Volume: 174, Issue:3 Topics: Arthritis, Rheumatoid; Fibroblasts; Humans; Janus Kinases; Oncostatin M; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors; Synovial Fluid; Synovial Membrane	2013
Summaries for patients: tofacitinib for the treatment of rheumatoid arthritis. Annals of internal medicine, 2013, Aug-20, Volume: 159, Issue:4 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Remission Induction; Treatment Outcome	2013
[A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)]. Revue medicale suisse, 2014, Jan-22, Volume: 10, Issue:414 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chronic Disease; Drug Approval; Humans; Inflammation; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rheumatic Diseases; Switzerland	2014
Recent trends in orthopedic surgery aiming to improve quality of life for those with rheumatoid arthritis: data from a large observational cohort. The Journal of rheumatology, 2014, Volume: 41, Issue:5 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Cohort Studies; Databases, Factual; Female; Humans; Japan; Joints; Male; Orthopedic Procedures; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Tacrolimus	2014
Comments on the paper showing an exceptionally favorable response to tofacitinib among Japanese rheumatoid patients and an issue surrounding clinical trial led by pharmaceutical company. Modern rheumatology, 2015, Volume: 25, Issue:3 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Pyrimidines; Pyrroles	2015
Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis & rheumatology (Hoboken, N.J.), 2014, Volume: 66, Issue:10 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Female; Herpes Zoster; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult	2014
Rheumatoid arthritis: can tofacitinib be used as first-line monotherapy for RA? Nature reviews. Rheumatology, 2014, Volume: 10, Issue:8 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles	2014
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA? The Korean journal of internal medicine, 2014, Volume: 29, Issue:5 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Piperidines; Pyrimidines; Pyrroles	2014
Tofacitinib versus methotrexate in rheumatoid arthritis. The New England journal of medicine, 2014, 09-18, Volume: 371, Issue:12 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles	2014
Tofacitinib versus methotrexate in rheumatoid arthritis. The New England journal of medicine, 2014, 09-18, Volume: 371, Issue:12 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles	2014
Tofacitinib versus methotrexate in rheumatoid arthritis. The New England journal of medicine, 2014, 09-18, Volume: 371, Issue:12 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles	2014
Rheumatoid arthritis in 2014: Exciting times for RA research. Nature reviews. Rheumatology, 2015, Volume: 11, Issue:2 Topics: Animals; Arthritis, Rheumatoid; Disease Models, Animal; Humans; Inflammation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocytes, Regulatory	2015
Response to Dr Minota's Letter to the Editor of Modern Rheumatology Regarding a Study of Tofacitinib in Japanese Patients with Rheumatoid Arthritis. Modern rheumatology, 2016, Volume: 26, Issue:2 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Immunomodulation; Male; Methotrexate; Pyrimidines; Pyrroles	2016
Super-enhancers delineate disease-associated regulatory nodes in T cells. Nature, 2015, Apr-23, Volume: 520, Issue:7548 Topics: Animals; Arthritis, Rheumatoid; Basic-Leucine Zipper Transcription Factors; Cell Differentiation; Cell Lineage; Enhancer Elements, Genetic; Gene Expression Regulation; Genetic Predisposition to Disease; Janus Kinase 3; Mice; Mice, Inbred C57BL; p300-CBP Transcription Factors; Piperidines; Pyrimidines; Pyrroles; RNA, Untranslated; T-Lymphocytes, Helper-Inducer; Transcription, Genetic	2015
Potent anti-inflammatory effects of the narrow spectrum kinase inhibitor RV1088 on rheumatoid arthritis synovial membrane cells. British journal of pharmacology, 2015, Volume: 172, Issue:15 Topics: Acetamides; Adalimumab; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Dasatinib; Dose-Response Relationship, Drug; Humans; Inflammation Mediators; Interleukin-6; Interleukin-8; Macrophages; Monocytes; Naphthalenes; Oxazines; Piperidines; Primary Cell Culture; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; RNA, Small Interfering; Signal Transduction; Synovial Membrane; Tumor Necrosis Factor-alpha; Urea	2015
Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea. Clinical therapeutics, 2015, Volume: 37, Issue:8 Topics: Adult; Arthritis, Rheumatoid; Cost-Benefit Analysis; Female; Humans; Janus Kinase 3; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality of Life; Republic of Korea; Severity of Illness Index; Surveys and Questionnaires	2015
Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice. Arthritis research & therapy, 2015, Dec-10, Volume: 17 Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Cyclohexylamines; Disease Models, Animal; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Immunophenotyping; Intracellular Signaling Peptides and Proteins; Janus Kinases; Male; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Syk Kinase	2015
Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases. Clinical therapeutics, 2016, Volume: 38, Issue:6 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Drug Costs; Female; Humans; Male; Medication Adherence; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies	2016
Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Annals of the rheumatic diseases, 2016, Volume: 75, Issue:10 Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Herpes Simplex; Herpes Zoster; Herpesviridae Infections; Humans; Incidence; Male; Middle Aged; Piperidines; Proportional Hazards Models; Pyrimidines; Pyrroles; Risk Factors; Sex Factors	2016
Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. Arthritis & rheumatology (Hoboken, N.J.), 2016, Volume: 68, Issue:11 Topics: Abatacept; Adult; Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Databases, Factual; Diverticulitis; Esophageal Perforation; Female; Gastroesophageal Reflux; Glucocorticoids; Humans; Incidence; Intestinal Perforation; Male; Medicare; Middle Aged; Peptic Ulcer; Piperidines; Prednisone; Proportional Hazards Models; Pyrimidines; Pyrroles; Risk Factors; Rituximab; Tumor Necrosis Factor-alpha; United States	2016
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. Drug safety, 2016, Volume: 39, Issue:8 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infant, Newborn; Methotrexate; Piperidines; Pregnancy; Pregnancy Outcome; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Young Adult	2016
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Seminars in arthritis and rheumatism, 2016, Volume: 46, Issue:3 Topics: Arthritis, Rheumatoid; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Heart Failure; Humans; Hyperlipidemias; Hypertension; Incidence; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Triglycerides	2016
Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib. Clinical rheumatology, 2017, Volume: 36, Issue:3 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Neoplasms; Opportunistic Infections; Piperidines; Pyrimidines; Pyrroles; Risk Assessment	2017
An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States. Journal of managed care & specialty pharmacy, 2016, Volume: 22, Issue:9 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Humans; Models, Economic; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome; United States	2016
Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation. Clinical immunology (Orlando, Fla.), 2016, Volume: 173 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Janus Kinase Inhibitors; Middle Aged; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome	2016
JAK inhibitors: A broadening approach in rheumatoid arthritis. Drugs of today (Barcelona, Spain : 1998), 2016, Volume: 52, Issue:8 Topics: Arthritis, Rheumatoid; Biosimilar Pharmaceuticals; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles	2016
Impact of tofacitinib treatment on human B-cells in vitro and in vivo. Journal of autoimmunity, 2017, Volume: 77 Topics: Antibody Formation; Arthritis, Rheumatoid; B-Lymphocytes; Cells, Cultured; Cytidine Deaminase; Humans; Immunoglobulin Class Switching; Immunomodulation; Interleukin Receptor Common gamma Subunit; Lymphocyte Activation; Lymphocyte Count; Piperidines; Plasma Cells; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction	2017
Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database. Journal of managed care & specialty pharmacy, 2016, Volume: 22, Issue:12 Topics: Abatacept; Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Databases, Factual; Etanercept; Female; Humans; Insurance Claim Review; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; United States	2016
Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria. Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:4 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Remission Induction	2017
Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Rheumatology (Oxford, England), 2017, Volume: 56, Issue:1 Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Cell Count; Clinical Trials, Phase III as Topic; Fatigue; Female; Hemoglobins; Humans; Longitudinal Studies; Lymphocyte Count; Male; Middle Aged; Neutrophils; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome	2017
Rheumatoid arthritis: TAK-ing the road to suppress inflammation in synovial fibroblasts. Nature reviews. Rheumatology, 2017, Volume: 13, Issue:3 Topics: Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Cytokines; Fibroblasts; Humans; Lactones; MAP Kinase Kinase Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Resorcinols; Synovial Membrane	2017
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Annals of the rheumatic diseases, 2017, Volume: 76, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Herpes Zoster; Humans; Immunocompromised Host; Incidence; Infections; Male; Middle Aged; Neoplasms; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Tuberculosis; Young Adult	2017
Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2017, Volume: 23, Issue:4 Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Janus Kinase Inhibitors; Latin America; Long Term Adverse Effects; Male; Middle Aged; Patient Safety; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2017
Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising. Arthritis research & therapy, 2017, 03-07, Volume: 19, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Comparative Effectiveness Research; Direct-to-Consumer Advertising; Herpes Zoster; Humans; Intestinal Perforation; Natural Language Processing; Piperidines; Pyrimidines; Pyrroles; Social Media	2017
Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis. Bioorganic & medicinal chemistry letters, 2017, 04-15, Volume: 27, Issue:8 Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Male; Mice, Inbred C57BL; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Structure-Activity Relationship	2017
Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. Journal of medical economics, 2017, Volume: 20, Issue:7 Topics: Abatacept; Adalimumab; Age Factors; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Cost-Benefit Analysis; Drug Therapy, Combination; Etanercept; Humans; Infliximab; Models, Economic; Piperidines; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Severity of Illness Index; Sex Factors; Time Factors; Tumor Necrosis Factor-alpha; United States	2017
Hydroxychloroquine-induced hyperpigmentation: the staining pattern. Journal of cutaneous pathology, 2008, Volume: 35, Issue:12 Topics: Aged; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Atorvastatin; Calcium Carbonate; Cardiomyopathy, Restrictive; Citalopram; Connective Tissue Diseases; Diuretics; Female; Furosemide; Glucosamine; Heptanoic Acids; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpigmentation; Lupus Erythematosus, Systemic; Magnesium; Metolazone; Middle Aged; Naproxen; Omeprazole; Potassium Chloride; Prednisone; Pyrroles; Selective Serotonin Reuptake Inhibitors; Spironolactone	2008
Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity. Bioorganic & medicinal chemistry letters, 2008, Dec-01, Volume: 18, Issue:23 Topics: Arthritis, Rheumatoid; Combinatorial Chemistry Techniques; Cytokines; Dose-Response Relationship, Drug; Drug Design; HSP27 Heat-Shock Proteins; Humans; Intracellular Signaling Peptides and Proteins; Leukocytes, Mononuclear; Lipopolysaccharides; Molecular Structure; Monocytes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Pyrimidinones; Pyrroles; Tumor Necrosis Factor-alpha	2008
Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scandinavian journal of rheumatology, 2009, Volume: 38, Issue:4 Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Arthritis, Rheumatoid; Atorvastatin; Biomarkers; Case-Control Studies; CD4-Positive T-Lymphocytes; CD8 Antigens; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Female; Fibroblasts; Flow Cytometry; Heptanoic Acids; HLA-DR Antigens; Humans; Interleukin-6; Lectins, C-Type; Leukocytes, Mononuclear; Male; Middle Aged; Probability; Pyrroles; Reference Values; Reverse Transcriptase Polymerase Chain Reaction; Synovial Membrane; T-Lymphocyte Subsets; Young Adult	2009
Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nature reviews. Drug discovery, 2010, Volume: 9, Issue:4 Topics: Administration, Oral; Aminopyridines; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Humans; Morpholines; Oxazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles	2010
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:4 Topics: Aged; Antineoplastic Agents; Arthritis, Rheumatoid; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Everolimus; Humans; Hypercholesterolemia; Hypertension; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Pyrroles; Randomized Controlled Trials as Topic; Salvage Therapy; Sirolimus; Sunitinib	2011
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases. Journal of medicinal chemistry, 2010, Sep-23, Volume: 53, Issue:18 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Arthritis, Rheumatoid; Biological Availability; Caco-2 Cells; Crystallography, X-Ray; Female; Humans; Hydrogen Bonding; In Vitro Techniques; Inflammation; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Microsomes, Liver; Mitogen-Activated Protein Kinase 14; Models, Molecular; Molecular Conformation; Protein Binding; Pyrroles; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Triazines; Tumor Necrosis Factor-alpha	2010
Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. Rheumatology (Oxford, England), 2011, Volume: 50, Issue:2 Topics: Aged; Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Statistics as Topic	2011
Estimating transformations for repeated measures modeling of continuous bounded outcome data. Statistics in medicine, 2011, Apr-30, Volume: 30, Issue:9 Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Computer Simulation; Data Interpretation, Statistical; Humans; Janus Kinase 3; Models, Statistical; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Surveys and Questionnaires; Treatment Outcome	2011
CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes. Arthritis research & therapy, 2011, May-06, Volume: 13, Issue:3 Topics: Antineoplastic Agents; Arthritis, Rheumatoid; Benzimidazoles; Cells, Cultured; Culture Media, Conditioned; Drug Interactions; Fibroblasts; Humans; Interleukin-6; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Oncostatin M; p38 Mitogen-Activated Protein Kinases; Piperidines; Pyridones; Pyrimidines; Pyrroles; RNA, Messenger; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; STAT5 Transcription Factor; Synovial Membrane	2011
Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nature biotechnology, 2011, Jun-07, Volume: 29, Issue:6 Topics: Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Drug Industry; Humans; Immunosuppression Therapy; Janus Kinases; Piperidines; Pyrimidines; Pyrroles; Receptors, Cytokine; Signal Transduction	2011
A case study of model-based Bayesian dose response estimation. Statistics in medicine, 2011, Sep-20, Volume: 30, Issue:21 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Chronic Disease; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Humans; Longitudinal Studies; Nonlinear Dynamics; Piperidines; Pyrimidines; Pyrroles	2011
Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium. The Journal of rheumatology, 2011, Volume: 38, Issue:11 Topics: Acute-Phase Reaction; Arthritis, Rheumatoid; Cells, Cultured; Enzyme Inhibitors; Humans; Interleukin-6; Janus Kinase 2; Janus Kinase 3; Janus Kinases; Piperidines; Pyrimidines; Pyrroles; RNA, Messenger; Serum Amyloid A Protein; Signal Transduction; STAT3 Transcription Factor; Synovial Membrane	2011
Inhibitory effects of the JAK inhibitor CP690,550 on human CD4(+) T lymphocyte cytokine production. BMC immunology, 2011, Aug-31, Volume: 12 Topics: Antibodies, Monoclonal; Arthritis, Rheumatoid; CD3 Complex; CD4-Positive T-Lymphocytes; Cells, Cultured; Cytokines; Humans; Immunosuppression Therapy; Janus Kinase 3; Lymphocyte Activation; Phosphorylation; Piperidines; Pyrimidines; Pyrroles; Receptors, Antigen, T-Cell; Signal Transduction; STAT Transcription Factors	2011
IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. International immunology, 2011, Volume: 23, Issue:11 Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Chronic Disease; Enzyme Inhibitors; Fibroblasts; Gene Expression; Humans; Inflammation; Interleukin-1beta; Interleukin-6; Joints; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Osteoclasts; Piperidines; Pyrimidines; Pyrroles; RANK Ligand; Signal Transduction; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha	2011
The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Annals of the rheumatic diseases, 2012, Volume: 71, Issue:3 Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Autocrine Communication; Cells, Cultured; Chemokines; Drug Evaluation, Preclinical; Fibroblasts; Humans; Interferon Type I; Interleukin-6; Janus Kinase 3; Mice; Phosphorylation; Piperidines; Pyrimidines; Pyrroles; STAT1 Transcription Factor; STAT3 Transcription Factor; Synovial Membrane; Tumor Necrosis Factor-alpha	2012
Sunitinib-induced hand-foot syndrome in a renal cell carcinoma: a sclerodermatous and rheumatoid arthritis-like case. The Journal of dermatology, 2012, Volume: 39, Issue:11 Topics: Aged; Antineoplastic Agents; Arthritis, Rheumatoid; Carcinoma, Renal Cell; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Pyrroles; Scleroderma, Diffuse; Sunitinib	2012
[Anti-rheumatic effect of JAK-inhibitors]. Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 2012, Volume: 35, Issue:2 Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Humans; Janus Kinases; Mice; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles	2012
Serious adverse events-missing in action: comment on the article by Kremer et al. Arthritis and rheumatism, 2012, Volume: 64, Issue:9 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Pyrimidines; Pyrroles	2012
Kinase inhibition--a new approach to the treatment of rheumatoid arthritis. The New England journal of medicine, 2012, Aug-09, Volume: 367, Issue:6 Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Enzyme Inhibitors; Female; Humans; Janus Kinase 3; Male; Piperidines; Pyrimidines; Pyrroles	2012
Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis. Arthritis research & therapy, 2012, Aug-17, Volume: 14, Issue:4 Topics: Arthritis, Rheumatoid; Atorvastatin; Cells, Cultured; Coculture Techniques; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Male; Osteoclasts; Osteogenesis; Pyrroles; RANK Ligand; Synovial Membrane	2012
Tofacitinib for the treatment of moderate to severe rheumatoid arthritis. Drugs of today (Barcelona, Spain : 1998), 2012, Volume: 48, Issue:8 Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Interactions; Humans; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index	2012
Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis and rheumatism, 2012, Volume: 64, Issue:12 Topics: Animals; Arthritis, Rheumatoid; Cells, Cultured; Disease Models, Animal; Enzyme Inhibitors; Humans; In Vitro Techniques; Inflammation; Interleukin-6; Janus Kinases; Macrophages; Mice; Mice, Inbred C57BL; NF-kappa B; NFATC Transcription Factors; Nitriles; Piperidines; Proto-Oncogene Proteins c-jun; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; STAT1 Transcription Factor; Synovial Membrane; Tumor Necrosis Factor-alpha	2012
FDA approves tofacitinib for rheumatoid arthritis. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2012, Dec-15, Volume: 69, Issue:24 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Approval; Humans; Piperidines; Pyrimidines; Pyrroles; United States; United States Food and Drug Administration	2012
Kinase inhibition in rheumatoid arthritis: a big advance? Lancet (London, England), 2013, Feb-09, Volume: 381, Issue:9865 Topics: Arthritis, Rheumatoid; Female; Humans; Janus Kinases; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha	2013
Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market. Nature biotechnology, 2013, Volume: 31, Issue:1 Topics: Arthritis, Rheumatoid; Drug Costs; Drug Industry; Humans; Janus Kinases; National Institutes of Health (U.S.); Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; United States	2013
RA gets first oral agent to compete with biologics. Managed care (Langhorne, Pa.), 2013, Volume: 22, Issue:1 Topics: Administration, Oral; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Clinical Trials, Phase III as Topic; Drug Approval; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Therapeutic Equivalency; United States; United States Food and Drug Administration	2013
Statins in rheumatoid arthritis--two birds with one stone? Lancet (London, England), 2004, Jun-19, Volume: 363, Issue:9426 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors	2004
Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Annals of the rheumatic diseases, 2004, Volume: 63, Issue:12 Topics: Adult; Aged; Arteries; Arthritis, Rheumatoid; Atorvastatin; Drug Evaluation; Elasticity; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Male; Middle Aged; Pulsatile Flow; Pyrroles; Radial Artery	2004
Rheumatoid arthritis treatment progressing. Health news (Waltham, Mass.), 2004, Volume: 10, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Cyclophosphamide; Drug Therapy, Combination; Heptanoic Acids; Humans; Methotrexate; Pyrroles; Rituximab	2004
Regulation of neurokinin-1 receptor messenger RNA expression in synovial fibroblasts of patients with rheumatoid arthritis. Neuropeptides, 2005, Volume: 39, Issue:5 Topics: Arthritis, Rheumatoid; Cells, Cultured; Fibroblast Growth Factors; Fibroblasts; Humans; Interleukin-1; Protein Isoforms; Pyrroles; Receptors, Neurokinin-1; Receptors, Neurokinin-2; RNA, Messenger; Synovial Membrane; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha	2005
Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis. Arthritis research & therapy, 2006, Volume: 8, Issue:4 Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Atorvastatin; CD55 Antigens; CD59 Antigens; Cells, Cultured; Cobalt; Cytoprotection; Deferoxamine; Diterpenes; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia; Iron Chelating Agents; Mevalonic Acid; Pyrroles; RNA, Messenger; Up-Regulation	2006
Atorvastatine for chronic synovitis due to massive intra-articular cholesterol monohydrate deposition in long-standing rheumatoid arthritis. Rheumatology (Oxford, England), 2006, Volume: 45, Issue:12 Topics: Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Cholesterol; Crystallization; Female; Heptanoic Acids; Humans; Middle Aged; Pyrroles; Synovitis	2006
Tolerizing DNA vaccines for autoimmune arthritis. Autoimmunity, 2006, Volume: 39, Issue:8 Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Atorvastatin; Autoantibodies; Collagen; Cytokines; Heptanoic Acids; Hindlimb; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-4; Joints; Male; Mice; Mice, Inbred DBA; Protein Array Analysis; Pyrroles; Systems Biology; Vaccines, DNA	2006
Arthritis clinical trial results revealed. JAMA, 2007, Jan-03, Volume: 297, Issue:1 Topics: Acetates; Antirheumatic Agents; Arthritis, Rheumatoid; Chondroitin Sulfates; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Osteoarthritis; Piperidines; Pyrimidines; Pyrroles	2007
The dual inhibitor of lipoxygenase and cyclooxygenase ML3000 decreases the expression of CXCR3 ligands. Annals of the rheumatic diseases, 2008, Volume: 67, Issue:4 Topics: Acetates; Arthritis, Rheumatoid; Cells, Cultured; Chemokines, CXC; Cyclooxygenase Inhibitors; Down-Regulation; Fibroblasts; Humans; Ligands; Lipoxygenase Inhibitors; Polymerase Chain Reaction; Pyrroles; Receptors, CXCR3; RNA, Messenger; Synovial Membrane	2008
The specificity of JAK3 kinase inhibitors. Blood, 2008, Feb-15, Volume: 111, Issue:4 Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Enzyme Inhibitors; Graft Rejection; Humans; Janus Kinase 3; Kinetics; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines	2008
Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis research & therapy, 2008, Volume: 10, Issue:1 Topics: Adjuvants, Immunologic; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Cartilage, Articular; Collagen; Dose-Response Relationship, Drug; Enzyme Inhibitors; Interleukin-6; Janus Kinase 3; Male; Mice; Mice, Inbred DBA; Piperidines; Pyrimidines; Pyrroles; Rats; Rats, Inbred Lew	2008
Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria. Annals of the rheumatic diseases, 1984, Volume: 43, Issue:3 Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Auranofin; Aurothioglucose; Female; Glomerulonephritis; Gold; Humans; Middle Aged; Proteinuria; Pyrroles; Tolmetin	1984
Enhancement of deficient T-cell function in rheumatoid arthritis by tolmetin sodium. Journal of clinical pharmacology, 1983, Volume: 23, Issue:7 Topics: Arthritis, Rheumatoid; Humans; In Vitro Techniques; Mitogens; Phytohemagglutinins; Pyrroles; T-Lymphocytes; Time Factors; Tolmetin	1983
Long-term therapy with tolmetin in rheumatoid arthritis. Journal of clinical pharmacology, 1983, Volume: 23, Issue:7 Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Double-Blind Method; Female; Humans; Male; Middle Aged; Pyrroles; Time Factors; Tolmetin	1983
Clinical pharmacology of tolmetin: comparisons in rheumatoid arthritis patients and normal volunteers. Journal of clinical pharmacology, 1983, Volume: 23, Issue:7 Topics: Adult; Arthritis, Rheumatoid; Biological Availability; Female; Half-Life; Humans; Kinetics; Male; Middle Aged; Prostaglandins E; Pyrroles; Synovial Fluid; Tolmetin	1983
Tolmetin kinetics and synovial fluid prostaglandin E levels in rheumatoid arthritis. Clinical pharmacology and therapeutics, 1982, Volume: 32, Issue:3 Topics: Adult; Arthritis, Rheumatoid; Female; Half-Life; Humans; Kinetics; Male; Middle Aged; Prostaglandins E; Pyrroles; Synovial Fluid; Tolmetin	1982
Simultaneous determination of tolmetin and its metabolite in biological fluids by high-performance liquid chromatography. Journal of chromatography, 1982, Oct-08, Volume: 232, Issue:1 Topics: Arthritis, Rheumatoid; Chromatography, High Pressure Liquid; Humans; Pyrroles; Synovial Fluid; Tolmetin	1982
Nephrotic syndrome induced by tolmetin. JAMA, 1981, Oct-02, Volume: 246, Issue:14 Topics: Arthritis, Rheumatoid; Aspirin; Female; Humans; Middle Aged; Nephritis, Interstitial; Nephrotic Syndrome; Pyrroles; Tolmetin	1981
Inhibition of NFkappaB-mediated interleukin-1beta-stimulated prostaglandin E2 formation by the marine natural product hymenialdisine. The Journal of pharmacology and experimental therapeutics, 1997, Volume: 283, Issue:2 Topics: Adult; Arthritis, Rheumatoid; Azepines; Cells, Cultured; Dinoprostone; Endothelial Growth Factors; Humans; Interleukin-1; Interleukin-8; Lymphokines; NF-kappa B; Phospholipases A; Phospholipases A2; Prostaglandin-Endoperoxide Synthases; Pyrroles; Synovial Membrane; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	1997
Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis. The Journal of rheumatology, 2001, Volume: 28, Issue:9 Topics: Acetates; Animals; Arachidonate 5-Lipoxygenase; Arthritis, Experimental; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Disease Models, Animal; Female; Lipoxygenase Inhibitors; Probability; Prostaglandin-Endoperoxide Synthases; Pyrroles; Range of Motion, Articular; Rats; Rats, Inbred Lew; Reference Values; Sensitivity and Specificity; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome	2001
New antirheumatic agents: Fenoprofen calcium (Nalfon), naproxen (Naprosyn), and tolmetin sodium (Tolectin). JAMA, 1977, Mar-21, Volume: 237, Issue:12 Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Fenoprofen; Gastrointestinal Hemorrhage; Humans; Naphthaleneacetic Acids; Naproxen; Osteoarthritis; Phenylpropionates; Pyrroles; Rheumatic Diseases; Spondylitis, Ankylosing; Tolmetin	1977
Tolmetin sodium. Arthritis and rheumatism, 1977, Volume: 20, Issue:4 Topics: Arthritis, Rheumatoid; False Positive Reactions; Female; Gold Sodium Thiomalate; Humans; Middle Aged; Proteinuria; Pyrroles; Tolmetin	1977
Absorption and excretion of tolmetin in arthritic patients. Clinical pharmacology and therapeutics, 1979, Volume: 26, Issue:1 Topics: Arthritis, Rheumatoid; Biotransformation; Chromatography, Thin Layer; Female; Humans; Intestinal Absorption; Kinetics; Male; Pyrroles; Tolmetin	1979
[Tolmetin (Tolectin) in the long-term therapy of progressive polyarthritis]. Fysiatricky a reumatologicky vestnik, 1978, Volume: 56, Issue:2 Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Pyrroles; Tolmetin	1978
Drug fever from tolmetin administration. JAMA, 1978, Jan-02, Volume: 239, Issue:1 Topics: Arthritis, Rheumatoid; Drug Hypersensitivity; Fever; Humans; Male; Middle Aged; Pyrroles; Tolmetin	1978
Nonsteroidal antiinflammatory drugs: new alternatives for rheumatic disease. Postgraduate medicine, 1978, Volume: 63, Issue:3 Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Fenoprofen; Humans; Ibuprofen; Naproxen; Phenylpropionates; Pyrroles; Tolmetin	1978
Tolmetin and agranulocytosis. The New England journal of medicine, 1978, May-25, Volume: 298, Issue:21 Topics: Agranulocytosis; Arthritis, Rheumatoid; Female; Humans; Middle Aged; Pyrroles; Tolmetin	1978
Anaphylaxis from tolmetin. JAMA, 1978, Jul-21, Volume: 240, Issue:3 Topics: Adult; Anaphylaxis; Arthritis, Rheumatoid; Female; Humans; Pruritus; Pyrroles; Tolmetin	1978
Protein binding of tolmetin. Clinical pharmacology and therapeutics, 1978, Volume: 24, Issue:6 Topics: Adult; Aged; Arthritis, Rheumatoid; Binding Sites; Binding, Competitive; Erythrocytes; Female; Humans; In Vitro Techniques; Male; Middle Aged; Oleic Acids; Plasma; Protein Binding; Pyrroles; Serum Albumin; Tolmetin; Tryptophan	1978
New nonsteroidal anti-inflammatory drugs. American family physician, 1976, Volume: 14, Issue:3 Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Fenoprofen; Humans; Ibuprofen; Naphthaleneacetic Acids; Naproxen; Phenylpropionates; Pyrroles; Tolmetin	1976
Pharmacokinetic studies of tolmetin in man. Clinical pharmacology and therapeutics, 1975, Volume: 17, Issue:5 Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Benzoates; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Kinetics; Male; Models, Biological; Pyrroles; Toluene	1975
[Testing of the antirheumatic agent tolmetin for its interactions with oral anticoagulants]. Schweizerische medizinische Wochenschrift, 1975, Jun-07, Volume: 105, Issue:23 Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Coagulation; Drug Interactions; Female; Humans; Male; Middle Aged; Phenprocoumon; Pyrroles; Tolmetin	1975
[Open trial for the evaluation of the therapeutic effectiveness of i-p chlorophenyl-2,5-dimethyl-3-pyrrole acetic acid (clopirac) in rheumatoid arthritis (author's transl)]. Journal belge de rhumatologie et de medecine physique = Belgisch tijdschrift voor reumatologie en fysische geneeskunde, 1975, Volume: 30 Spec no Topics: Arthritis, Rheumatoid; Drug Evaluation; Female; Humans; Male; Pyrroles	1975
[Pharmacological study of clopirac, a new anti-inflammatory agent (author's transl)]. Journal belge de rhumatologie et de medecine physique = Belgisch tijdschrift voor reumatologie en fysische geneeskunde, 1975, Volume: 30 Spec no Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Evaluation; Prostaglandins; Pyrroles; Rats	1975
[Review of the clinical studies in rheumatoid arthritis with several non steroid anti-inflammatory agents (author's transl)]. Journal belge de rhumatologie et de medecine physique = Belgisch tijdschrift voor reumatologie en fysische geneeskunde, 1975, Volume: 30 Spec no Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Evaluation; Humans; Indomethacin; Ketoprofen; Phenylbutazone; Pyrroles	1975
Tolmetin in breast milk. Drug intelligence & clinical pharmacy, 1985, Volume: 19, Issue:1 Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Milk, Human; Pyrroles; Tolmetin	1985
Clinical evaluation of tolmetin. Current medical research and opinion, 1974, Volume: 2, Issue:6 Topics: Administration, Oral; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Benzoates; Female; Humans; Male; Middle Aged; Pain; Pyrroles; Radioisotopes; Statistics as Topic; Technetium	1974
Pharmacologic evaluation of tolectin (tolmetin, mcn-2559) and mcn-2891, two anti-inflammatory agents. The Journal of pharmacology and experimental therapeutics, 1973, Volume: 185, Issue:1 Topics: Acetylcholine; Analysis of Variance; Animals; Anti-Inflammatory Agents; Arthritis; Arthritis, Rheumatoid; Behavior, Animal; Benzoates; Blood Pressure; Carrageenan; Dose-Response Relationship, Drug; Edema; Female; Freund's Adjuvant; Heart; Indomethacin; Male; Osteoarthritis; Phenylbutazone; Pyrroles; Quinones; Rats; Saccharomyces cerevisiae; Toluene	1973
Haem biosynthesis studied in patients with rheumatoid arthritis. Journal of clinical pathology, 1972, Volume: 25, Issue:2 Topics: Anemia, Hypochromic; Arthritis, Rheumatoid; Erythrocytes; Heme; Humans; Hydro-Lyases; Levulinic Acids; Porphyrins; Pyrroles	1972
Diaryl pyrroles: a new series of anti-inflammatory agents. Experientia, 1972, Aug-15, Volume: 28, Issue:8 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Disease Models, Animal; Edema; Erythema; Female; Guinea Pigs; Hindlimb; Injections, Subcutaneous; Male; Pyrroles; Rats	1972